







The response to HIV in western and central Africa



The text of the report has been extracted from the Global AIDS update 2021: Confronting inequalities—Lessons for pandemic responses from 40 years of AIDS. Copyright © 2021 Joint United Nations Programme on HIV/AIDS (UNAIDS) All rights reserved. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of UNAIDS concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. UNAIDS does not warrant that the information published in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use. UNAIDS/JC3020E/Western and central Africa

# **CONTENTS**

How to end the AIDS epidemic in western and central Africa	02
Western and central Africa	04
Country data sheets	16
Benin	16
Burkina Faso	18
Burundi	20
Cabo Verde	22
Cameroon	24
Central African Republic	26
Chad	28
Congo	30
Côte d'Ivoire	32
Democratic Republic of the Congo	34
Equatorial Guinea	36
Gabon	38
Gambia	40
Ghana	42
Guinea	44
Guinea-Bissau	46
Liberia	48
Mali	50
Mauritania	52
Niger	54
Nigeria	56
Sao Tome and Principe	58
Senegal	60
Sierra Leone	62
Table	/ /

# HOW TO END THE AIDS EPIDEMIC IN WESTERN AND CENTRAL AFRICA

The AIDS epidemic in western and central Africa is an ongoing emergency. The early gains made against HIV in this region have not been translated into the sustained progress that has been made in other parts of sub-Saharan Africa.

Last year, there were 150 000 AIDS-related deaths in the region, and 200 000 people became newly infected with HIV. Every week more than 1000 adolescent girls and young women aged 15–24 years become infected with HIV in the region; 1.2 million people in western and central Africa are still waiting to initiate life-saving HIV treatment. Only 35% of children living with HIV in western and central Africa are on treatment.

Now the COVID-19 crisis has obstructed services and exacerbated the inequalities that drive the AIDS epidemic. If we don't act now, not only will many more lives be lost, but containing the AIDS pandemic will be more difficult and expensive in the coming years.

Ending AIDS is achievable: there is a tested set of approaches that are proven to work, including in challenging settings.

From Cabo Verde's leadership on the elimination of vertical transmission of HIV, to Cameroon's decision last year to eliminate user fees for all HIV services at public health facilities and accredited community sites, examples that light the way are already there. By aligning policy with the evidence of what has succeeded, we can end AIDS as we promised.

Countries and communities are already leveraging the experience and expertise of the AIDS response to reduce the impact of COVID-19 across this region. From Côte d'Ivoire, to Guinea, to Senegal, public health authorities, international organizations, civil society actors and communities of people living with and affected by HIV have worked together to ensure that people living with HIV continue to receive their medication, to deliver care and prevention services in safe and innovative ways, to deliver food to people who have lost their incomes in lockdown, to convey messages about the importance of hygiene and social distancing in order to stay well and to dispel myths that feed stigma and discrimination and weaken public health messaging.

This spirit of cooperation and partnership is vital for stronger pandemic responses.

This week, hosted by the President of Senegal, Macky Sall, UNAIDS and the Civil Society Institute for HIV and Health in West and Central Africa are organizing a summit in Dakar on how to close the gaps in the region's HIV response and strengthen pandemic preparedness.

Here are three of the bold actions we need to take.

First, embrace and enable communities to be at the centre of planning and delivery.

Communities know the situation on the ground—they must be given

the resources and the space to lead. Countries need to ensure an enabling environment for communities to be involved in providing services as an integral part of the public health response, be involved as co-planners, be able to highlight experiences and concerns and be able to play their essential role ensuring accountability.

Countries need to lift those legal, policy and programmatic barriers that hold this back, and to scale up financial support to unleash the incomparable contribution of communities

Second, increase investment.

Countries need to increase the scale of provision in prevention, testing and treatment and eliminate all financial barriers to ensure universal access to services.

The Abuja commitment to invest 15% of government budgets in public health needs to be met. Joint commitments made by health and finance ministers at the Africa Leadership Meeting to increase domestic revenues dedicated to health must be fulfilled.

International donors too have to step up with support at the time of the worst crisis in decades. Enabling the required fiscal space will require debt cancellation to support governments in scaling up investments in health and in tackling the social drivers of HIV and pandemic risk.

International action to prevent harmful tax competition and illicit



financial flows is likewise key. It is difficult to advance towards fair and progressive taxation, and grow revenues, when large corporations and high-net-worth individuals are systemically enabled internationally to evade the taxes the ordinary citizen must pay, and which are essential for health, education, social protection and economic investment.

Third, address the inequalities that drive the epidemic.

COVID-19 has once again shown the world how epidemics thrive on inequalities, both between countries and within them. The new UNAIDS strategy adopted earlier this year puts the fight to end inequalities at the centre of the mission to end AIDS.

Inequalities drive HIV. Vulnerable groups of people represent 44% of new HIV infections in western and central Africa. Their partners represent a further 27%.

The ECOWAS Strategy for HIV, TB, Hepatitis B & C and Sexual and Reproductive Health and Rights among Key Populations puts it so well:

"the protection of human rights for all members of each key population is crucial to success. Laws that discriminate or create barriers should be reformed, to ensure that key populations are free from stigma, discrimination and violence and their vulnerability to HIV is reduced."

Gender inequality likewise drives HIV: of the new HIV infections among young people in western and central Africa, almost three quarters are among adolescent girls and young women. The issue is power.

Research shows that ensuring that girls complete secondary education reduces their risk of acquiring HIV by up to half, and that combining this with a package of services and rights for girls' empowerment reduces their risk further still.

The Education Plus initiative, coconvened by UNICEF, UNESCO, UNFPA, UN Women and UNAIDS, with governments, civil society and international partners, is helping to accelerate the actions and investments needed to ensure that every African girl is in school, safe and strong.

What we need to do to end AIDS is also what we need to do to enable Africa to rise.

Governments, international organizations, scientists, researchers, community-led organizations and civil society actors cannot be successful alone, but together they can create an unbeatable partnership and an unstoppable force to end AIDS as a public health threat by 2030.

### Winnie Byanyima

**UNAIDS** Executive Director

# WESTERN AND CENTRAL AFRICA



he HIV response across western and central Africa is improving, but not fast enough to end AIDS as a public health threat by 2030. Over the past year, the COVID-19 pandemic has disrupted HIV and other health services, and it has highlighted the vulnerability of people in the region to public health, climatic, socioeconomic and security shocks, along with the pressing need for inclusive social protection systems.

There were 37% fewer new HIV infections in the region in 2020 compared with 2010—steady progress, but far short of the 75% reduction agreed by the United Nations (UN) General Assembly. The region also accounted for more than one third of new HIV infections among children globally in 2020, reflecting ongoing gaps in efforts to prevent vertical transmission, including low coverage of maternal and newborn health services. Overall, 44% of pregnant women living with HIV in western and central Africa were not receiving antiretroviral therapy in 2020.

Key populations and their sexual partners accounted for 72% of new adult HIV infections, and women and girls (aged 15 to 49 years) represented 65%. Adolescent girls and young women continue to be heavily affected by HIV, with a relatively high prevalence of violence against women and girls a contributing risk factor.

Coverage of HIV testing and antiretroviral therapy has grown at a quicker pace in recent years, with nearly three quarters (73%) of people living with HIV receiving antiretroviral therapy in 2020 and 59% virally suppressed. However, just 24% of children (aged 0 to 14 years) living with HIV were virally suppressed in the same year, with poor case finding and linkage to treatment the major gaps.

Stronger political leadership and effective multisectoral partnerships are essential for making health systems more resilient, mobilizing increased domestic resources for high-impact interventions, allocating those resources for programmes focusing on key populations, and removing the user fees and other legal and policy barriers that deter the uptake of life-saving services.


Reaching HIV service targets for 2025 requires addressing human rights and gender barriers, including HIV-related stigma and discrimination, criminalization of key populations and other punitive laws, and the traditional gender roles that condone violence and disempower women and girls. There is also a need to continue the transformation of health systems by promoting peoplecentered service modalities.


Community-based and other civil society organizations (such as faith-based organizations) are playing stronger roles in the regional response. These organizations are crucial to reaching key and other neglected populations with suitable services, including scaling up access to pre-exposure prophylaxis (PrEP). The West and Central Africa Civil Society Institute is expected to help expand such activities, with the objective of expanding community-led services in the region.

# PRIORITY ACTIONS FOR ENDING AIDS

- Reduce stigma and discrimination and gender-based violence by transforming harmful gender and other discriminatory social norms, and by creating an enabling environment for health.
- Ensure preparedness for comprehensive HIV service delivery during humanitarian emergencies and pandemics.
- Scale up high-impact combination HIV prevention for key populations and adolescent girls and young people.
- Strengthen peoplecentred health systems, including community systems, to deliver results for the most vulnerable.
- Close gaps in service availability and the uptake of paediatric HIV treatment to prevent vertical transmission.
- Promote an accountable, inclusive and sustainable HIV response through multisectoral partnerships, including for issues beyond HIV.
- Establish health situation rooms, improve resource tracking and develop new analytics for epidemiological estimates, including analysis of the contributions of key populations to specific epidemics.

FIGURE 1.1 | PROPORTION OF CHILDREN (AGED 0-14 YEARS) LIVING WITH HIV WITH SUPPRESSED VIRAL LOAD, WESTERN AND CENTRAL AFRICA, 2016-2020






Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

The single biggest paediatric treatment challenge in western and central Africa is to rapidly find children who are living with HIV and link them to care. Just 24% of children living with HIV in the region had suppressed viral loads in 2020 (Figure 1.1). Family-based index testing and integrating HIV screening with other child health services are critical to closing this gap. Data show that once children are diagnosed and linked to care, the majority do well, with seven in 10 on treatment having suppressed viral loads.


# STATE OF THE PANDEMIC

FIGURE 1.2 | **NUMBER OF NEW HIV INFECTIONS AND AIDS-RELATED DEATHS, WESTERN AND CENTRAL AFRICA, 2000–2020** 




Source: UNAIDS epidemiological estimates, 2021 (https://aidsinfo.unaids.org/).

FIGURE 1.3 | **DISTRIBUTION OF NEW HIV INFECTIONS BY POPULATION GROUP AND SEX (AGED 15–49 YEARS), WESTERN AND CENTRAL AFRICA, 2020** 



Source: UNAIDS special analysis, 2021 (see methods annex).

# FIGURE 1.4 | HIV PREVALENCE AMONG KEY POPULATIONS, REPORTING COUNTRIES IN WESTERN AND CENTRAL AFRICA, 2016–2020



- Sex workers (n = 19)
- Gay men and other men who have sex with men (n = 19)
- People who inject drugs (n = 7)
- Transgender people (n = 5)
- Prisoners (n = 15)

Source: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/). Note: (n = number of countries). Total number of reporting countries = 25.

#### How to read this chart




TABLE 1.1 | REPORTED ESTIMATED SIZE OF KEY POPULATIONS, WESTERN AND CENTRAL AFRICA, 2018–2020

	National adult population (aged 15–49 years) in 2020 or relevant year	Sex workers	Sex workers as per cent of adult population (aged 15–49 years)	Gay men and other men who have sex with men	Gay men and other men who have sex with men as per cent of adult population (aged 15–49 years)	People who inject drugs	People who inject drugs as per cent of adult population (aged 15–49 years)	Transgender people	Transgender people as per cent of adult population (aged 15–49 years)	Prisoners	Prisoners as per cent of adult population (aged 15–49 years)
Cameroon	12 900 000										
Central African Republic	2 300 000	3900		3000							
Chad	7 500 000	19 500		2100		700					
Côte d'Ivoire	12 900 000			56 000		3000		700		42 400	0.33%
Democratic Republic of the Congo	49 300 000	350 000	0.76%			156 000	0.34%			36 700	0.07%
Gambia	1 100 000			1700						700	0.06%
Mali	9 000 000	18 100		4100							
Mauritania	2 100 000	8500		7600							
Nigeria	103 000 000					326 000	0.32%				
Niger	10 100 000			53 700	0.53%						
Senegal	7 900 000			52 500	0.66%	900	0.01%			11 000	0.14%
Togo	4 000 000									5000	0.13%
Estimated regional proportion as per cadult population (aged 15–49 years)	cent of		0.60%		0.64%		0.05%		-		-

Local population size estimate

No data

Sources: UNAIDS Global AIDS Monitoring, 2021 (https://aidsinfo.unaids.org/); Spectrum Demproj module, 2021.

Note 1: Estimates shown are government-provided estimates reported for 2018–2020. Additional and alternative estimates may be available from different sources, including the Key Populations Atlas (https://kpatlas.unaids.org/), academic publications or institutional documents. Note 2: The regions covered by the local population size estimate are as follows:

Central African Republic: Capitale (Bangui), prefectures (Berbérati and Bouar), subprefectures (Boali and Carnot).

Chad: Eleven cities in the country.

Côte d'Ivoire: Abengourou, Abidjan, Bouaké, Divo, Gagnoa, Issia, Korhogo, Man, Ouangolodougou, San-Pédro and Yakro (gay men and other men who have sex with men); Bouaké, San-Pédro and Yamoussoukro (people who inject drugs); Abidjan (transgender people). Gambia: Banjul.

Mali: Bamako, Kayes, Koulikoro, Mopti, Ségou and Sikasso (sex workers); Bamako, Gao, Kayes, Koulikoro, Mopti, Ségou and Sikasso (gay men and other men who have sex with men).

Mauritania: The six biggest cities in the country.


Note 3: The reported values for gay men and other men who have sex with men are presented as a per cent of the adult population (aged 15–49 years) for consistency across key populations. The percentage of this population out of the adult male population (aged 15-49 years) will be approximately twice the values shown.

<sup>&</sup>lt;sup>a</sup> Quick Start Guide for Spectrum, 2020. Geneva: UNAIDS; 2020 (https://www.unaids.org/sites/default/files/media\_asset/QuickStartGuide\_ Spectrum\_en.pdf).

<sup>&</sup>lt;sup>b</sup> Technical brief: recommended population size estimates of men who have sex with men. Geneva: WHO, UNAIDS; 2020.


# HIV SERVICES


FIGURE 1.5 | **PEOPLE LIVING WITH HIV, PEOPLE NEWLY INFECTED IN THE PAST SIX MONTHS, AND HIV TESTING AND TREATMENT CASCADE, ADULTS (AGED 15+ YEARS), WESTERN AND CENTRAL AFRICA, 2016–2020** 




Source: UNAIDS special analysis, 2021.

FIGURE 1.6 | HIV TESTING AND TREATMENT CASCADE, CHILDREN (AGED 0-14 YEARS) COMPARED TO ADULTS (AGED 15 YEARS AND OLDER), WESTERN AND CENTRAL AFRICA, 2020







#### Adults (aged 15 years and older) living with HIV




Source: UNAIDS special analysis, 2021.

FIGURE 1.7 | **HIV TESTING AND TREATMENT CASCADE, WOMEN (AGED 15+ YEARS) COMPARED TO MEN (AGED 15+ YEARS), WESTERN AND CENTRAL AFRICA, 2020** 





#### Men (aged 15+ years) living with HIV



Source: UNAIDS special analysis, 2021.

# LAWS AND POLICIES

TABLE 1.2 | **PUNITIVE AND DISCRIMINATORY LAWS, WESTERN AND CENTRAL AFRICA, 2021** 

POLICIES	Criminalization of transgender people	Criminalization of sex work	Criminalization of same-sex sexual acts	Law allows for possession of a certain limited amount of drugs for personal use	Parental consent for adolescents to access HIV testing	Laws criminalizing the transmission of non-disclosure of or exposure to HIV transmission	Laws or policies restricting the entry, stay and residence of people living with HIV	Mandatory HIV testing for marriage, work or residence permits or for certain groups
Benin	1		1					1
Burkina Faso	1	5	1	1				1
Burundi	3	6	14			23		17
Cabo Verde			14			23		
Cameroon	1							1
Central African Republic	1		1					1
Chad	1				18	24		1
Congo	2		2					2
Côte d'Ivoire	1							1
Democratic Republic of the Congo	2		2		19	23		2
Equatorial Guinea	1	9	1		20			1
Gabon	2	10	14					1
Gambia		11	14			23		1
Ghana	2					2		2
Guinea	2	12	15					1
Guinea-Bissau	2		2	28	21	23		2
Liberia	2					2		2
Mali	1		1		22			1
Mauritania	1		1	1				1
Niger	1							1
Nigeria	1					1		1
Sao Tome and Principe	2	2	2					2
Senegal	1		16			1		1
Sierra Leone	1	13				25		1
Togo	1							1

#### Criminalization of transgender people

- Criminalized and/or prosecuted
- Neither criminalized nor prosecuted
- Data not available

#### Criminalization of sex work

- Any criminalization or punitive regulation of sex work
- Sex work is not subject to punitive regulations or is not criminalized
- Issue is determined/differs at the subnational level
- Data not available

#### Criminalization of same-sex sexual acts

- Death penalty
- Imprisonment (14 years–life, up to 14 years) or no penalty specified
- Laws penalizing same-sex sexual acts have been decriminalized or never existed, or no specific legislation
- Data not available

# Law allows for possession of a certain limited amount of drugs for personal use

- No
- Yes
- Data not available

#### Parental consent for adolescents to access HIV testing

- Yes, for adolescents younger than 18
- Yes, for adolescents younger than 14 or 16
- Yes, for adolescents younger than 12
- No
- Data not available

# Laws criminalizing the transmission of, non-disclosure of or exposure to HIV transmission

- Ye:
- No, but prosecutions exist based on general criminal laws
- No
- Data not available

# Laws or policies restricting the entry, stay and residence of people living with HIV

- Deport, prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Prohibit short and/or long stay and require HIV testing or disclosure for some permits
- Require HIV testing or disclosure for some permits
- No restrictions
- Data not available

# Mandatory HIV testing for marriage, work or residence permits or for certain groups

- Yes
- No
- Data not available

#### Sources


- 1. UNAIDS National Commitments and Policy Instrument, 2021 (see http://lawsandpolicies.unaids.org/).
- 2. UNAIDS National Commitments and Policy Instrument, 2019 (see http://lawsandpolicies.unaids.org/).
- 3. UNAIDS National Commitments and Policy Instrument, 2017 (see http://lawsandpolicies.unaids.org/).
- 4. Benin. Penal Code 2018 (https://assemblee-nationale.bj/wp-content/uploads/2020/03/le-nouveau-code-penal-2018.pdf).
- 5. Burkina Faso. Penal Code 2019. Article 533-20; Burkina Faso. Loi no. 025-2018. Articles 533-20, 533-27, 533-28 (https://www.refworld.org/docid/3ae6b5cc0.html).
- 6. Burundi. Penal Code 2009. Article 538 and 548 (https://ihl-databases.icrc.org/applic/ihl/ihl-nat.nsf/0/ cb9d300d8db9fc-37c125707300338af2/\$FILE/Code%20P%c3%a9nal%20du%20Burundi%20.pdf).
- 7. Cabo Verde. Penal Code, 2004. Article 148 (https://www.wipo.int/edocs/lexdocs/laws/pt/cv/cv001pt. pdf).
- 8. Côte d'Ivoire. Penal Code (https://www.refworld.org/docid/3ae6b5860.html%22%3Ehttp://www.refworld.org/docid/3ae6b5860.html%22%3Ehttp://www.refworld.org/docid/3ae6b5860.html%3C/a%3E%3C/p&gt).
- 9. Equatorial Guinea. Penal Code. Article 452(bis) (https://acjr.org.za/resource-centre/penal-code-ofequatorial-guinea-1963/view).
- 10. Gabon. Penal Code, 2018. Article 402-1 (http://www.droit-afrique.com/uploads/Gabon-Code-2019- penal.pdf).
- 11. Gambia. Criminal Code. Article 248 (https://www.wipo.int/edocs/lexdocs/laws/en/mu/mu008en. pdf).
- 12. Guinea. Penal Code. Articles 346 and 351 (https://www.refworld.org/docid/44a3eb9a4.html).
- 13. Sierra Leone. Sexual Offences Act. Article 17 (http://www.sierra-leone.org/Laws/2012-12.pdf).
- 14. Mendos LR. State-sponsored homophobia, 2020. Geneva: International Lesbian, Gay, Bisexual, Trans and Intersex Association; December 2020 (https://ilga.org/downloads/ILGA\_State\_Sponsored\_Homophobia\_2019\_light.pdf).
- 15. Guinea. Penal Code 2016. Article 274 (https://www.refworld.org/docid/44a3eb9a4.html).
- Senegal. Code Penal. Art 319 (https://www.ilo.org/dyn/natlex/docs/ELECTRONIC/70562/85594/F-2143944421/SEN-70562. pdf)
- 17. UNAIDS National Commitments and Policy Instrument, 2018 (see http://lawsandpolicies.unaids.org/).
- 18. Chad. Loi N°019/PR/2007 du 15 Novembre 2007 portant lutte contre VIH/SIDA/IŜT et protection des Droits des Personnes Vivant avec le VIH/SIDA. Articles 10 and 21 (https://www.ilo.org/wcmsp5/groups/public/---ed\_protect/---protrav/---ilo\_aids/documents/legaldocument/wcms\_126793.pdf).
- 19. Sexual Rights Initiative database [database]. Sexual Rights Initiative; c2016 (http://sexualrightsdatabase.org/map/21/Adult%20 sex%20work).
- 20. Equatorial Guinea. Article 25 Ley N 3/2005 de fecha 9 de mayo sobre la prevencion y la lucha contra las infecciones de transmision sexual/VIH SIDA y la defensa de los derechos humanos de las personas afectada.
- 21. Guinea. Loi L/2005025/AN. Adoptant et promulguant la loi relative à la prévention, la prise en charge et le contrôle du VIH/SIDA, 2005 (http://www.ilo.org/aids/legislation/lang--en/index.htm).
- 22. Mali. Normes et Procédures des Services de Dépistage du VIH au Mali: Haut Conseil National de Lutte Contre le SIDA, 2017.
- 23. Global HIV Criminalisation Database [database]. Amsterdam: HIV Justice Network (https://www.hivjustice.net/global-hiv-criminalisation-database/).
- 24. Chad. Loi N°019/PR/2007 du 15 novembre 2007 portant lutte contre VIH/SIDA/IST et protection des Droits des Personnes Vivant avec le VIH/SIDA. Articles 50–55 (https://www.ilo.org/wcmsp5/groups/public/---ed\_protect/---protrav/---ilo\_aids/documents/legaldocument/wcms\_126793.pdf).
- 25. Sierra Leone. Prevention and Control of HIV and AIDS Act 2007. Section 21.3 (https://sierralii.org/sl/legislation/act/2007/8).
- 26. Still not welcome: HIV-related travel restrictions. Geneva: UNAIDS, UNDP; 2019 (https://www.unaids.org/sites/default/files/media\_asset/hiv-related-travel-restrictions-explainer\_en.pdf).
- 27. Côte d'Ivoire. Loi organique no. 2014-424 du 14 juillet 2014. Article 4 (https://www.pnlsci.com/wp-content/uploads/2020/08/LOI-VIH-PROMULGUEE.pdf).
- 28. Guinea-Bissau. Decreto-Lei n° 2-B, de 28 de Outubro de 1993 (https://fecongd.org/pdf/crianca/CodigoPenal.pdf).

Note: A country is considered to have criminalized transgender persons if it uses the law to punish transgender individuals. Such a law may, for example, explicitly criminalize impersonation of the other gender, including cross-dressing. A country is considered to have any criminalization or punitive regulation of sex work if selling and/or buying sexual services is criminalized, ancillary activities associated with selling and/or buying sexual services are criminalized, profiting from organizing and/or managing sexual services is criminalized, and/or there are other punitive and/or administrative regulations of sex work.

# INVESTING TO END AIDS

There is a substantial funding gap in western and central Africa. The resources available for HIV responses in the region in 2020 were approximately two thirds the amount needed in 2025. Total HIV resources in the region declined by 11% between 2010 and 2020. Domestic resources have increased by 6% during the last decade, peaking in 2018 before declining by 15% over the next two years. The sources of international funding have changed significantly in the region. The United States President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) increased their contributions to the region by 23% and 85%, respectively, between 2010 and 2020, while all other international resources have reduced their contributions by 79%. Both external and domestic resources need to grow in order to meet the 2025 targets. Resource availability per person living with HIV will have to be increased from the current US\$ 398 in 2020 to US\$ 539 by 2025.


FIGURE 1.8 | RESOURCE AVAILABILITY FOR HIV, WESTERN AND CENTRAL AFRICA, 2010–2020, AND ESTIMATED RESOURCE NEEDS FOR HIV BY 2025



Source: UNAIDS financial estimates and projections, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

Note: The resource estimates are presented in constant 2019 US dollars.

FIGURE 1.9 | YEAR-TO-YEAR CHANGE IN RESOURCE AVAILABILITY FOR HIV, WESTERN AND CENTRAL AFRICA, 2010–2011 TO 2019–2020



Source: UNAIDS financial estimates, 2021 (http://hivfinancial.unaids.org/hivfinancialdashboards.html).

#### References

- Regional analysis of countries survey on situation and need of people living with HIV in the context of Covid-19. Geneva: UNAIDS, NAP+; 2021.
- 2. Una G, Allen R, Pattanayak S, Suc G. Digital solutions for direct cash transfers in emergencies. Washington (DC): International Monetary Fund (https://www.imf.org/~/media/Files/Publications/covid19-special-notes/en-special-series-on-covid-19-digital-solutions-for-direct-cash-transfers-in-emergencies.ashx).
- 3. Beegle K, Coudouel A, Monsalve E. Realizing the full potential of social safety nets in Africa. Washington (DC): World Bank; 2018 (https://openknowledge.worldbank.org/bitstream/handle/10986/29789/9781464811647. pdf?sequence=2&isAllowed=y).
- 4. Synthesis report: WFP/UNAIDS cash transfer pilot initiative in west and central Africa (draft). Geneva: UNAIDS; April
- 5. The state of the world's cash 2020. Cash and voucher assistance in humanitarian aid. The Cash Learning Partnership; 2020 (https://www.calpnetwork.org/wp-content/uploads/2020/07/SOWC2020-Full-Report.pdf).
- 6. Beegle K, Coudouel A, Monsalve E, editors. Realizing the full potential of social safety nets in Africa. Washington (DC): World Bank Group, Agence Française de Développement; 2018 (https://openknowledge.worldbank.org/bitstream/handle/10986/29789/9781464811647.pdf?sequence=2&isAllowed=y).

BENIN COUNTRY DATA

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	5000	3900	2300
	[4100–6300]	[2900–5600]	[1600–4000]
New HIV infections (0–14)	2000	1500	670
	[1600–2500]	[1000–2100]	[500–1400]
New HIV infections (women, 15+)	1700	1500	1000
	[1300–2300]	[1100–2300]	[710–1800]
New HIV infections (men, 15+)	1200	910	550
	[970–1700]	[670–1400]	[<500–950]
HIV incidence per 1000 population	0.56 [0.46–0.71]	0.39 [0.29–0.55]	0.19 [0.14–0.34]
AIDS-related deaths			
AIDS-related deaths (all ages)	2600	2700	2000
	[2100–3400]	[2000–3700]	[1500–3000]
AIDS-related deaths (0–14)	1500	1300	690
	[1200–1800]	[960–1700]	[<500–1200]
AIDS-related deaths (women, 15+)	500	530	550
	[<500–730]	[<500–860]	[<500–850]
AIDS-related deaths (men, 15+)	690	890	800
	[<500–980]	[640–1300]	[630–1100]
People living with HIV			
People living with HIV (all ages)	68 000	75 000	75 000
	[59 000–79 000]	[65 000–88 000]	[65 000–94 000]
People living with HIV (0–14)	13 000	12 000	8900
	[11 000–15 000]	[9600–14 000]	[7000–12 000]
People living with HIV (women, 15+)	34 000	39 000	43 000
	[29 000–39 000]	[34 000–47 000]	[37 000–53 000]
People living with HIV (men, 15+)	22 000	23 000	23 000
	[19 000–26 000]	[21 000–28 000]	[21 000–29 000]
HIV prevalence (15–49)	1.2 [1–1.4]	1.1 [1–1.3]	0.9 [0.8–1.2]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2018 refers to women only)	<b>2014</b> 67.1	<b>2018</b> 73
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced		2018
physical or sexual violence from a male intimate partner in the past 12 months		13.9

STIGMA AND DISCRIMINATION

<b>EXPENDITURES</b>						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020		US\$ 8 629 360		US\$ 12 671 466	US\$ 200 183	US\$ 22 220 326


#### **EPIDEMIC TRANSITION METRICS**



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	8.5%	7%	2.2%	21.9%	4.1%
HIV testing and status awareness	59.2%	84.1%	71.2%	88.5%	
Antiretroviral therapy coverag					
Condom use	83.5%	66%	51.8%	86.8%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2020)	720 072				

#### **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	13% [10–15%]	98% [75–100%]
Final vertical transmission rate including during breastfeeding	30.2% [28.2–32.2%]	11.2% [9.4–16.9%]
Early infant diagnosis	% [–%]	38.4% [29.5–50%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	940 [610–1400]
People living with HIV who started TB preventive therapy (2018)	7.1%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.4%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	15%
— Men	18.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	22.9%
— Men	36%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	28.8%
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Harm reduction	
<ul> <li>Use of sterile injecting equipment at</li> </ul>	04.404

<ul> <li>Use of sterile injecting equipment at last injection (2017)</li> </ul>	94.6%
<ul> <li>Needles and syringes distributed per person who injects</li> </ul>	
<ul> <li>Coverage of opioid substitution therapy</li> </ul>	
— Naloxone available (2021)	No

No

- Safe injection rooms available (2021)

	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	6300	2600	2100	
	[4800–8000]	[1800–3600]	[1200–3100]	
New HIV infections (0–14)	4200	1300	1300	
	[3100–5200]	[960–1800]	[800–2100]	
New HIV infections (women, 15+)	1100	730	<500	
	[800–1600]	[<500–1200]	[<500–770]	
New HIV infections (men, 15+)	1000	560	<500	
	[700–1500]	[<500–940]	[<200–540]	
HIV incidence per 1000 population	0.42 [0.32–0.54]	0.15 [0.11–0.21]	0.1 [0.06–0.15]	
AIDS-related deaths				
AIDS-related deaths (all ages)	7200	5300	3300	
	[5500–9300]	[4000–6800]	[2400–4300]	
AIDS-related deaths (0–14)	3300	2200	1100	
	[2500–4100]	[1500–2700]	[780–1700]	
AIDS-related deaths (women, 15+)	1900	1100	780	
	[1400–2600]	[840–1500]	[560–1000]	
AIDS-related deaths (men, 15+)	2000	2100	1400	
	[1500–2600]	[1600–2600]	[1000–1800]	
People living with HIV				
People living with HIV (all ages)	120 000	110 000	97 000	
	[100 000–140 000]	[93 000–130 000]	[81 000–110 000]	
People living with HIV (0–14)	35 000	25 000	16 000	
	[28 000–42 000]	[19 000–31 000]	[12 000–21 000]	
People living with HIV (women, 15+)	47 000	48 000	49 000	
	[40 000–54 000]	[41 000–56 000]	[40 000–56 000]	
People living with HIV (men, 15+)	39 000	36 000	32 000	
	[33 000–46 000]	[31 000–41 000]	[28 000–37 000]	
HIV prevalence (15–49)	1.1 [0.9–1.3]	0.9 [0.7–1]	0.7 [0.5–0.8]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or	No

residence permits or for certain groups

#### **STIGMA AND DISCRIMINATION**

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	
	 •••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	•••
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	•••


#### **VIOLENCE**

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2017 US\$ 2 875 787 US\$ 18 027 894 ... US\$ 14 293 173 US\$ 3 858 466 US\$ 39 055 319






<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

#### **KEY POPULATIONS** Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population ... **HIV** prevalence 5.4% 1.9% 2.2% HIV testing and status 67.9% 74.7% awareness Antiretroviral therapy coverage 92.9% Condom use 87.2% Coverage of HIV prevention 46.8% 76.4% ... programmes Avoidance of health care because of stigma and $\ discrimination$ **Expenditures in US\$** ... ...

#### **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	21% [17–26%]	89% [69–100%]
Final vertical transmission rate including during breastfeeding	31.6% [29.7–33.4%]	12% [9.2–16.1%]
Early infant diagnosis	7.1% [5.6–9.7%]	10% [8.4–12.8%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	930 [600–1300]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2010)	
— Women	31.1%
— Men	35.8%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2010)	
— Women	59%
— Men	74.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2010)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

#### Harm reduction


<ul> <li>Use of sterile injecting equipment at last injection</li> </ul>	
<ul> <li>Needles and syringes distributed per</li> </ul>	

person	n who injects	•••
— Covera	age of opioid substitution by	

погару	
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

## **BURUNDI**

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	4300	2800	1700	
	[3200–5500]	[1900–4000]	[1100–2600]	
New HIV infections (0–14)	1900	1200	950	
	[1500–2400]	[790–1600]	[640–1300]	
New HIV infections (women, 15+)	1300	960	<500	
	[820–1700]	[550–1400]	[<500–780]	
New HIV infections (men, 15+)	1100	690	<500	
	[680–1700]	[<500–1100]	[<200–510]	
HIV incidence per 1000 population	0.52 [0.39–0.67]	0.29 [0.2–0.41]	0.15 [0.1–0.22]	
AIDS-related deaths				
AIDS-related deaths (all ages)	5900	3500	1700	
	[4900–7000]	[2700–4300]	[1300–2200]	
AIDS-related deaths (0–14)	1700	1000	680	
	[1400–2000]	[720–1300]	[<500–940]	
AIDS-related deaths (women, 15+)	2200	960	<500	
	[1700–2700]	[660–1300]	[<500–540]	
AIDS-related deaths (men, 15+)	2000	1500	600	
	[1600–2500]	[1200–1900]	[<500–790]	
People living with HIV				
People living with HIV (all ages)	95 000	87 000	83 000	
	[86 000 <b>–1</b> 10 000]	[78 000–98 000]	[73 000–95 000]	
People living with HIV (0–14)	20 000	14 000	9700	
	[17 000–23 000]	[11 000–16 000]	[7300–12 000]	
People living with HIV (women, 15+)	43 000	43 000	44 000	
	[39 000–48 000]	[39 000–48 000]	[39 000–50 000]	
People living with HIV (men, 15+)	32 000	30 000	29 000	
	[29 000–38 000]	[27 000–34 000]	[26 000–33 000]	
HIV prevalence (15–49)	1.6 [1.5–1.8]	1.3 [1.1–1.4]	1 [0.9–1.1]	




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014	US\$ 2 098 404	US\$ 289 800		US\$ 15 903 384	US\$ 122 941	US\$ 18 414 529

**COUNTRY DATA** 

#### HIV TESTING AND TREATMENT CASCADE




All ages	89% [79–100%]	88% [78–100%] 73 033	79% [70–91%]
Children (0-14)	31% [24–39%]	31% [24–39%] 3042	22% [17–27%]
Women (15+)	>98% [94–100%]	>98% [94–100%] 46 179	96% [85–100%]
Men (15+)	85% [76–95%]	82% [73–92%] 23 812	73% [66–82%]

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	38% [32–45%]	55% [45–63%]		
Final vertical transmission rate including during breastfeeding	28.1% [25.5–30.4%]	16.4% [13.4–20.6%]		
Early infant diagnosis	8.6% [6.9 <b>–1</b> 1%]	80.2% [69.5– >95%]		

# **CABO VERDE**

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)			
	[]	[]	[]
New HIV infections (0–14)			
	[–]	[]	[]
New HIV infections (women, 15+)			
	[–]	[]	[]
New HIV infections (men, 15+)			
	[]	[–]	[]
HIV incidence per 1000 population	[]	[]	[]
AIDS-related deaths			
AIDS-related deaths (all ages)	<100	<100	<100
	[<100- <200]	[<100- <100]	[<100- <100]
AIDS-related deaths (0–14)			
	[]	[]	[]
AIDS-related deaths (women, 15+)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100- <100]
AIDS-related deaths (men, 15+)	<100	<100	<100
	[<100- <100]	[<100- <100]	[<100–<100]
People living with HIV			
People living with HIV (all ages)	1900	2100	2400
	[1600–2300]	[1800–2400]	[2000–2900]
People living with HIV (0-14)			
	[]	[]	[]
People living with HIV (women, 15+)	890	1000	1200
	[730–1100]	[890–1200]	[1000–1400]
People living with HIV (men, 15+)	900	1000	1200
	[750–1100]	[890–1200]	[980–1400]
HIV prevalence (15–49)	0.6 [0.5–0.7]	0.6 [0.5–0.7]	0.5 [0.4–0.7]




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014	US\$ 93 000	US\$ 2 343 480	US\$ 28 723	US\$ 1 076 920	US\$ 269 531	US\$ 3 811 654

**COUNTRY DATA** 

#### HIV TESTING AND TREATMENT CASCADE



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	% [–%]	% [–%]		
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]		
Early infant diagnosis	% [–%]	%		


	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	35 000	24 000	15 000
	[31 000–41 000]	[20 000–28 000]	[12 000–19 000]
New HIV infections (0–14)	8300	4000	4500
	[6800–10 000]	[2800–5300]	[2900–5600]
New HIV infections (women, 15+)	17 000	13 000	7600
	[15 000–21 000]	[11 000–17 000]	[5900–10 000]
New HIV infections (men, 15+)	9400	6100	3000
	[7800–12 000]	[4900–8000]	[2200–4100]
HIV incidence per 1000 population	1.83 [1.62–2.12]	1.07 [0.9–1.27]	0.6 [0.47–0.75]
AIDS-related deaths			
AIDS-related deaths (all ages)	26 000	25 000	14 000
	[23 000–31 000]	[21 000–29 000]	[12 000–17 000]
AIDS-related deaths (0–14)	7100	4100	3500
	[6000–8100]	[3100–5000]	[2500–4400]
AIDS-related deaths (women, 15+)	13 000	12 000	5800
	[11 000–16 000]	[9700–14 000]	[4500–7400]
AIDS-related deaths (men, 15+)	5900	8900	4800
	[4800–8400]	[7700–11000]	[4000–5800]
People living with HIV			
People living with HIV (all ages)	520 000	520 000	500 000
	[490 000–570 000]	[490 000–560 000]	[470 000–540 000]
People living with HIV (0-14)	56 000	45 000	35 000
	[48 000–62 000]	[38 000–52 000]	[27 000–41 000]
People living with HIV (women, 15+)	300 000	310 000	310 000
	[280 000–330 000]	[290 000–340 000]	[290 000–340 000]
People living with HIV (men, 15+)	160 000	160 000	150 000
	[150 000–180 000]	[150 000–180 000]	[140 000–160 000]
HIV prevalence (15–49)	4.3 [4.1–4.5]	3.7 [3.4–3.9]	3 [2.7–3.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	The law allows possession of a certain amount of drugs
Criminalization of transgender people	Prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	N	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	•••	
	•••	•••
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2014	2018
physical or sexual violence from a male intimate partner in the past 12 months	32.7	20

<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 13 745 789	US\$ 14 805 716	US\$ 12 252 577	US\$ 14 302 281	US\$ 17 442 940	US\$ 72 549 303


#### **EPIDEMIC TRANSITION METRICS**



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population				•••	
HIV prevalence	24.3%	20.6%			4%
HIV testing and status awareness	97.0%	67.3%			
Antiretroviral therapy coverage	99.1%	97.2%			
Condom use	96%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination	4.7%	13.5%			
Expenditures in US\$					

#### **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION** 2010 2020 40% 64% Percentage of pregnant women living with HIV

accessing antiretroviral medicines	[34–47%]	[50–74%]
Final vertical transmission rate including during breastfeeding	24.2% [23.1–25.6%]	17.1% [14.3–19.2%]
Early infant diagnosis	20.4%	52.6%

[16.8-26.9%]

[45.6-67%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	13 000 [8700 –19 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### **HIV PREVENTION**

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15-24 years (2018)

— Women	40.6%
— Men	35.8%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years (2018)

— vvomen	43.4%
— Men	62.6%

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

performed according to national standards

Men aged	15-49 years who	are circumcised	Not
(2011)			applicable

(2011)	applicable
Voluntary medical male circumcisions	Not

applicable

No

People who received PrEP at least once during the reporting period (2020)	1969

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)

- Safe injection rooms available (2021) No

# **CENTRAL AFRICAN REPUBLIC**

**COUNTRY DATA** 

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)			
	[–]	[–]	[]
lew HIV infections (0–14)			
	[]	[–]	[]
lew HIV infections (women, 15+)			
	[]	[–]	[]
lew HIV infections (men, 15+)			
	[]	[]	[]
IIV incidence per 1000 population	[]	[]	[]
IDS-related deaths			
IDS-related deaths (all ages)	7900	5800	3200
	[6300–9700]	[4500–7200]	[2300–4400]
IDS-related deaths (0–14)	1500	880	<500
	[1200–1800]	[660–1200]	[<500–730]
IDS-related deaths (women, 15+)	3700	2900	1200
	[2900–4700]	[2300–3500]	[800–1700]
NDS-related deaths (men, 15+)	2700	2000	1500
	[2100–3500]	[1500–2600]	[1100–2000]
eople living with HIV			
eople living with HIV (all ages)	120 000	100 000	88 000
	[110 000–140 000]	[84 000–120 000]	[73 000–110 000]
eople living with HIV (0-14)	13 000	8900	5800
	[11 000–16 000]	[7200–11 000]	[4500–7800]
eople living with HIV (women, 15+)	65 000	53 000	51 000
	[57 000–75 000]	[45 000–62 000]	[42 000–61 000]
eople living with HIV (men, 15+)	47 000	37 000	31 000
	[40 000–54 000]	[31 000–45 000]	[26 000–39 000]
IIV prevalence (15–49)	5 [4.4–5.9]	3.9 [3.3–4.6]	2.9 [2.4–3.6]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

		MOITANIN

Percentage of women and men aged 15-49

years who report discriminatory attitudes towards people living with HIV	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their	

#### **VIOLENCE**


consent

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2018 US\$ 696 331 US\$ 799 650 ... US\$ 8 075 418 ... US\$ 10 943 141






<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	15%	6.5%			3.6%
HIV testing and status awareness	57.1%	61.8%			
Antiretroviral therapy coverag	61.4%	60%			
Condom use	79.6%	30%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination	84.8%				
Expenditures in US\$					

#### **HIV TESTING AND TREATMENT CASCADE**



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV	33%	71%		

accessing antiretroviral medicines	[28-41%]	[55–90%]
Final vertical transmission rate including during breastfeeding	% [–%]	% [–%]
	~1%	20.8%

Early infant diagnosis [<1-<1%] [23.6-38.4%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	6600 [4200 –9400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

#### **HIV PREVENTION**

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15-24 years (2010)

— Women	17.4%
— Men	25%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49 years

Women	

- Men

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15-49 years who are circumcised

Voluntary medical male circumcisions performed according to national standards

People who received PrEP at least once during the reporting period


#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021) No

Yes

### **CHAD**

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7100	5300	3500
	[5500–9000]	[3600–7300]	[2200–5700]
New HIV infections (0–14)	2600	1700	1000
	[1900–3500]	[1100–2500]	[600–1700]
New HIV infections (women, 15+)	2700	2200	1700
	[1900–3500]	[1600–3200]	[1000–2600]
New HIV infections (men, 15+)	1900	1300	850
	[1300–2500]	[910–2000]	[520–1400]
HIV incidence per 1000 population	0.62 [0.48–0.79]	0.39 [0.27–0.54]	0.22 [0.14–0.36]
AIDS-related deaths			
AIDS-related deaths (all ages)	4200	3800	3000
	[3000–5900]	[2500–5200]	[2000–4300]
AIDS-related deaths (0–14)	2100	1300	850
	[1600–2700]	[870–1900]	[520–1400]
AIDS-related deaths (women, 15+)	1200	1300	970
	[690–1800]	[750–1800]	[630–1400]
AIDS-related deaths (men, 15+)	930	1200	1200
	[560–1500]	[790–1700]	[760–1600]
People living with HIV			
People living with HIV (all ages)	110 000	110 000	110 000
	[87 000–130 000]	[91 000–130 000]	[90 000–130 000]
People living with HIV (0–14)	17 000	14 000	11 000
	[13 000–23 000]	[11 000–19 000]	[7600–15 000]
People living with HIV (women, 15+)	53 000	59 000	63 000
	[43 000–64 000]	[49 000–69 000]	[51 000–75 000]
People living with HIV (men, 15+)	36 000	39 000	38 000
	[29 000–45 000]	[32 000–46 000]	[32 000–46 000]
HIV prevalence (15–49)	1.6 [1.3–1.9]	1.4 [1.1–1.6]	1.1 [0.9–1.3]



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 123 770	US\$ 4 622 591		US\$ 7 037 322	US\$ 2 509 164	US\$ 17 632 654

**COUNTRY DATA** 

#### HIV TESTING AND TREATMENT CASCADE

70% [58–83%]

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION					
	2010	2020			
Percentage of pregnant women living with HIV accessing antiretroviral medicines	19% [15–23%]	87% [65–100%]			
Final vertical transmission rate including during breastfeeding	30.3% [28.2–32.8%]	14.5% [10.6–19.4%]			
Early infant diagnosis	2.3% [1.7–3.1%]	21.9% [17.6–29.4%]			

65% [53–76%]

24 785

...% [...-...%]

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7200	8600	10000
	[5100–9300]	[4800–13000]	[4500–22000]
New HIV infections (0–14)	1800	1800	2100
	[1400–2300]	[1200–2600]	[1100–3700]
New HIV infections (women, 15+)	3600	4800	5900
	[2400–4700]	[2600–7700]	[2300–13000]
New HIV infections (men, 15+)	1800	2000	2100
	[1200–2300]	[1100–3200]	[840–4600]
HIV incidence per 1000 population	1.77 [1.26–2.28]	1.87 [1.03–2.95]	1.94 [0.86–4.19]
AIDS-related deaths			
AIDS-related deaths (all ages)	5200	5500	6100
	[4300–6100]	[4300–6700]	[4100–8500]
AIDS-related deaths (0–14)	1400	1300	1500
	[1100–1700]	[900–1700]	[890–2300]
AIDS-related deaths (women, 15+)	2700	2700	3200
	[2200–3200]	[2100–3300]	[2100–4300]
AIDS-related deaths (men, 15+)	1100	1500	1500
	[860–1300]	[1200–1800]	[980–1900]
People living with HIV			
People living with HIV (all ages)	88 000	98 000	110 000
	[76 000–100 000]	[76 000–120 000]	[80 000–170 000]
People living with HIV (0-14)	10 000	9900	11 000
	[8500–12 000]	[7800–12 000]	[7600–15 000]
People living with HIV (women, 15+)	53 000	60 000	72 000
	[45 000–60 000]	[46 000–72 000]	[50 000–110 000]
People living with HIV (men, 15+)	26 000	28 000	31 000
	[22 000–29 000]	[22 000–34 000]	[22 000–46 000]
HIV prevalence (15–49)	3.4 [2.9–3.9]	3.3 [2.6–4.2]	3.3 [2.2–5.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV		
Percentage of people living with HIV denied health services because of their HIV status in	2015	
the last 12 months	6.1	
Percentage of people living with HIV who reported a health-care professional told	2015	
others about their HIV status without their consent	17.9	
VIOLENCE		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced		
physical or sexual violence from a male		

STIGMA AND DISCRIMINATION


intimate partner in the past 12 months

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2010	***	US\$ 8 104 228	***	US\$ 6 354 280	US\$ 1 676 938	US\$ 16 472 586

#### **EPIDEMIC TRANSITION METRICS**







Change in new
HIV infections = 41%
since 2010

Change in AIDS-related deaths = 18% since 2010

Incidence:
prevalence = 8.86
ratio

Incidence: mortality ratio\*


<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population		•••		•••		
HIV prevalence	8.1%	41.2%			3.9%	
HIV testing and status awareness						
Antiretroviral therapy coverag						
Condom use	86.3%	64.1%				
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination	17.2%	10.4%				
Expenditures in US\$						

HIV COMORBIDITIES	$\mathbf{r}$	M	19224	IIIES
	 CO	IVIC	TAP I	

Estimated number of incident tuberculosis cases among people living with HIV (2018)	5700 [2900 –9400]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### HIV TESTING AND TREATMENT CASCADE



#### HIV PREVENTION

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

Knowledge of HIV prevention among young people aged 15–24 years (2015)

— Women	26.7%
— Men	45.3%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)

— Women	38.3%
— Men	58%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not
(2012)	applicable

Voluntary medical male circumcisions	Not
performed according to national standards	applicable

People who received PrEP at least once during the reporting period

#### ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	11% [9–14%]	14% [8–22%]		
Final vertical transmission rate including during breastfeeding	32.5% [30.8–34.5%]	32.5% [29.8–35.7%]		
Early infant diagnosis	8.1% [6.5–10.8%]	<1% [<1–1.6%]		

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

# CÔTE D'IVOIRE

**COUNTRY DATA** 

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	22 000	12 000	6200	
	[17 000–30 000]	[9000–17 000]	[3500–10 000]	
New HIV infections (0–14)	5200	1700	1200	
	[3800–6700]	[1300–2800]	[510–2200]	
New HIV infections (women, 15+)	9600	6500	3200	
	[7300–13 000]	[4600–8800]	[2000–5000]	
New HIV infections (men, 15+)	7400	4100	1800	
	[5700–12 000]	[3000–6300]	[1100–3000]	
HIV incidence per 1000 population	1.14 [0.88–1.53]	0.55 [0.4–0.77]	0.24 [0.14–0.39]	
AIDS-related deaths				
AIDS-related deaths (all ages)	31 000	20 000	9400	
	[25 000–38 000]	[16 000–26 000]	[7300–12 000]	
AIDS-related deaths (0–14)	5200	2400	800	
	[4100–6300]	[1900–3200]	[510–1200]	
AIDS-related deaths (women, 15+)	13 000	8700	3900	
	[10 000–16 000]	[6800–11 000]	[3100–5100]	
AIDS-related deaths (men, 15+)	13 000	9200	4700	
	[11 000–17 000]	[7400–12 000]	[3600–6300]	
People living with HIV				
People living with HIV (all ages)	500 000	430 000	380 000	
	[440 000–580 000]	[380 000–490 000]	[340 000–430 000]	
People living with HIV (0–14)	60 000	37 000	21 000	
	[51 000–69 000]	[30 000–44 000]	[16 000–27 000]	
People living with HIV (women, 15+)	260 000	250 000	240 000	
	[240 000–300 000]	[220 000–280 000]	[210 000–270 000]	
eople living with HIV (men, 15+)	170 000	150 000	120 000	
	[150 000–210 000]	[130 000–170 000]	[110 000–140 000]	
HIV prevalence (15–49)	3.8 [3.4–4.1]	2.8 [2.5–3.1]	2.1 [1.8–2.3]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


residence permits or for certain groups

STIGMA AND DISCRIMINATION	NC	
Percentage of women and men aged 15–49 years who report discriminatory attitudes	2012	2016
towards people living with HIV (2016 refers to women only)	44.5	53
Percentage of people living with HIV denied		2016
the last 12 months		2.4
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		2016
consent		3.4
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

US\$ 21 902 421 ... US\$ 21 902 421 Last available report: 2016






<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population			***	***	42 400	
HIV prevalence	4.8%	7.7%	3.4%	24.7%	1.2%	
HIV testing and status awareness	99.4%	100%				
Antiretroviral therapy coverage					93.8%	
Condom use	63.1%	83.2%	24.9%			
Coverage of HIV prevention programmes	96.2%	39.1%				
Avoidance of health care because of stigma and discrimination	13.9%	5.5%	9.3%	22.6%		
Expenditures in US\$ (2012)	1 232 054	245 854	25 480			

#### **HIV TESTING AND TREATMENT CASCADE**



# **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	51% [41–60%]	89% [70–100%]
Final vertical transmission rate including during breastfeeding	22.7% [20.2–25.1%]	7.8% [3.9–12.2%]
Early infant diagnosis	25.3% [20.9–33.4%]	60.8% [52.2–77.3%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	7100 [4500 –10 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### HIV PREVENTION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.9%
Knowledge of HIV prevention among young people aged 15–24 years (2015)	
— Women	24%
— Men	33%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2016)	
— Women	30.4%
— Men	41.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2016)	33.7%
Men aged 15–49 years who are circumcised (2012)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	345
Harm reduction	

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

## **DEMOCRATIC REPUBLIC OF THE CONGO**

**COUNTRY DATA** 

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	39 000	30 000	20 000
	[32 000–47 000]	[23 000–37 000]	[13 000–29 000]
New HIV infections (0–14)	15 000	10 000	8800
	[13 000–18 000]	[7600–13 000]	[6200–12 000]
New HIV infections (women, 15+)	17 000	15 000	8500
	[14 000–22 000]	[11 000–19 000]	[5000–14 000]
New HIV infections (men, 15+)	6600	4700	2300
	[5100–8900]	[3400–6800]	[1400–3900]
HIV incidence per 1000 population	0.51 [0.41–0.61]	0.33 [0.25–0.41]	0.18 [0.12–0.28]
AIDS-related deaths			
AIDS-related deaths (all ages)	42 000	32 000	17 000
	[35 000–49 000]	[25 000–38 000]	[13 000–22 000]
AIDS-related deaths (0–14)	12 000	8700	7200
	[9900–14 000]	[6900–10 000]	[5200–9000]
AIDS-related deaths (women, 15+)	22 000	16 000	6500
	[18 000–26 000]	[12 000–19 000]	[4500–9000]
AIDS-related deaths (men, 15+)	8000	7200	3200
	[6400–9800]	[5600–8900]	[2500–4200]
People living with HIV			
People living with HIV (all ages)	540 000	510 000	510 000
	[470 000–610 000]	[430 000–580 000]	[430 000–580 000]
People living with HIV (0–14)	98 000	82 000	71 000
	[83 000–110 000]	[68 000–95 000]	[56 000–85 000]
People living with HIV (women, 15+)	310 000	300 000	310 000
	[270 000–360 000]	[260 000–350 000]	[270 000–360 000]
People living with HIV (men, 15+)	130 000	120 000	120 000
	[110 000–150 000]	[100 000–140 000]	[110 000–140 000]
HIV prevalence (15–49)	1.1 [1–1.3]	0.9 [0.8–1]	0.7 [0.6–0.9]

L	A۱.	NS	Αľ	ND	РО	LICI	ES	

residence permits or for certain groups

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	
Spousal consent for married women to access sexual and reproductive health services	
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

#### **STIGMA AND DISCRIMINATION**


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	<b></b>	
Percentage of people living with HIV denied		2012
the last 12 months		6.1
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		

#### **VIOLENCE**

Proportion of ever-married or partnered women aged 15-49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES							
Financing sources							
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total	


Last available report: 2017 US\$ 600 897 US\$ 18 662 067 US\$ 60 388 722 US\$ 79 284 139 US\$ 5 177 947 US\$ 174 572 249



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population	350 300	•••	155 800	•••	36 700	
HIV prevalence	7.5%	7.1%	3.9%		2.5%	
HIV testing and status awareness						
Antiretroviral therapy coverag						
Condom use	73.9%	50.6%	26.5%			
Coverage of HIV prevention programmes						
Avoidance of health care because of stigma and discrimination						
Expenditures in US\$ (2014)	6188	185 650				

#### **HIV TESTING AND TREATMENT CASCADE**



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	6% [5–7%]	39% [31–47%]		
Final vertical transmission rate including during breastfeeding	38.8% [36.9–40.7%]	27.8% [23.9–30.4%]		
Early infant diagnosis	2.5% [1.9–3.3%]	10.6% [8.9–13.7%]		

HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	31 000 [9400 -65 000]
People living with HIV who started TB preventive therapy (2018)	38.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	27.8%

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	27.8%
HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	•••
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	18.6%
— Men	24.9%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	22.6%
— Men	30.7%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	553
Harm reduction	
<ul> <li>Use of sterile injecting equipment at last injection (2019)</li> </ul>	50.6%
<ul> <li>Needles and syringes distributed per person who injects (2020)</li> </ul>	0
— Coverage of opioid substitution	


therapy

— Naloxone available (2021)

- Safe injection rooms available (2021)

# **EQUATORIAL GUINEA**

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)				
	[]	[–]	[]	
New HIV infections (0–14)				
	[]	[–]	[]	
New HIV infections (women, 15+)				
	[]	[–]	[]	
New HIV infections (men, 15+)				
	[]	[]	[]	
HIV incidence per 1000 population	[]	[]	[]	
AIDS-related deaths				
AIDS-related deaths (all ages)	1500	1800	2300	
	[1100–2000]	[1300–2400]	[1600–3400]	
AIDS-related deaths (0–14)	<500	<500	<500	
	[<500-<500]	[<500–530]	[<500–770]	
AIDS-related deaths (women, 15+)	560	<500	<500	
	[<500–780]	[<500–680]	[<500–810]	
AIDS-related deaths (men, 15+)	530	990	1300	
	[<500–770]	[740–1300]	[1000–1800]	
People living with HIV				
People living with HIV (all ages)	34 000	52 000	68 000	
	[28 000–42 000]	[43 000–63 000]	[52 000–94 000]	
People living with HIV (0–14)	2200	2800	3500	
	[1700–2700]	[2200–3500]	[2600–4900]	
People living with HIV (women, 15+)	16 000	25 000	35 000	
	[14 000–20 000]	[21 000–31 000]	[27 000–48 000]	
People living with HIV (men, 15+)	16 000	24 000	29 000	
	[13 000–19 000]	[20 000–30 000]	[22 000–41 000]	
HIV prevalence (15–49)	5.7 [4.7–6.8]	6.8 [5.7–8.6]	7.3 [5.5–10.3]	




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2013	US\$ 260 066	US\$ 7 844 051			US\$ 132 193	US\$ 8 715 789

**COUNTRY DATA** 

#### **HIV TESTING AND TREATMENT CASCADE**

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	15% [12–18%]	31% [22–44%]		
Final vertical transmission rate including during breastfeeding	% [%]	% [–%]		
Early infant diagnosis	% [–%]	4.5% [3.2–6.3%]		

21% [16–29%]

6042

...% [...-...%]

37% [28–52%]

**GABON COUNTRY DATA** 

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)	2500	1800	1000	
	[1900–3400]	[1100–2700]	[520–2100]	
New HIV infections (0–14)	730	510	<500	
	[560–990]	[<500–720]	[<200-<500]	
New HIV infections (women, 15+)	1200	910	570	
	[850–1800]	[530–1500]	[<500–1200]	
New HIV infections (men, 15+)	550	<500	<200	
	[<500–820]	[<500–590]	[<100-<500]	
HIV incidence per 1000 population	1.64 [1.23–2.23]	0.96 [0.61–1.46]	0.48 [0.24–0.99]	
AIDS-related deaths				
AIDS-related deaths (all ages)	2400	1600	930	
	[1600–3500]	[1000–2300]	[630–1400]	
AIDS-related deaths (0–14)	610	<500	<500	
	[<500–820]	[<500–570]	[<200–<500]	
AIDS-related deaths (women, 15+)	1400	780	<500	
	[940–2000]	[<500–1200]	[<500–720]	
AIDS-related deaths (men, 15+)	<500	<500	<500	
	[<500–690]	[<500–580]	[<200-<500]	
People living with HIV				
People living with HIV (all ages)	45 000	47 000	46 000	
	[37 000–56 000]	[39 000–56 000]	[38 000–56 000]	
People living with HIV (0–14)	3900	3400	2900	
	[3000–5200]	[2600–4500]	[2100–3700]	
People living with HIV (women, 15+)	28 000	30 000	30 000	
	[23 000–35 000]	[25 000–35 000]	[25 000–37 000]	
People living with HIV (men, 15+)	13 000	14 000	13 000	
	[11 000–16 000]	[12 000–16 000]	[11 000–16 000]	
HIV prevalence (15–49)	4.4 [3.6–5.3]	3.7 [3.1–4.3]	3 [2.4–3.7]	

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Laws penalizing same-sex sexual acts have been decriminalized or never existed
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	Yes

residence permits or for certain groups

CTICL	<i>A</i> A A B I	D DISC	BILLIAIRI	
			RIMINI	4 I II INI


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	<b></b>	
Percentage of people living with HIV denied health services because of their HIV status in		2013
the last 12 months		13.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••

## **VIOLENCE**

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 5 551 216 US\$ 5 825 622 Last available report: 2018



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence					
HIV testing and status awareness					
Antiretroviral therapy coverag					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

#### **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

2010	2020
21%	90%
[17–27%]	[67–100%]
23.9%	10%
[22.3–25.5%]	[7.4–14.9%]
4.6%	2.5%
[3.6–6.6%]	[1.9–3.4%]
	21% [17–27%] 23.9% [22.3–25.5%] 4.6%

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	4100 [1700 –7600]
People living with HIV who started TB preventive therapy (2018)	
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2019)	0.4%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment (2019)	100%

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2012)	
— Women	29.8%
— Men	36.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	54.5%
— Men	74.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2012)	Not applicable

Not

applicable

## Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

Voluntary medical male circumcisions

performed according to national standards

People who received PrEP at least once

during the reporting period

- Naloxone available (2021)
- Safe injection rooms available (2021)

GAMBIA COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	2000	2100
	[1700–2800]	[1500–2800]	[1300–3400]
New HIV infections (0–14)	<500	<500	<500
	[<500-<500]	[<200-<500]	[<500–550]
New HIV infections (women, 15+)	1000	1000	1000
	[810–1300]	[720–1400]	[630–1700]
New HIV infections (men, 15+)	760	750	740
	[580–990]	[540–1000]	[<500–1300]
HIV incidence per 1000 population	1.25 [0.97–1.61]	1.03 [0.75–1.43]	0.93 [0.59–1.51]
AIDS-related deaths			
AIDS-related deaths (all ages)	1300	1200	1300
	[960–1700]	[880–1600]	[880–1800]
AIDS-related deaths (0–14)	<500	<500	<500
	[<500–<500]	[<200-<500]	[<200-<500]
AIDS-related deaths (women, 15+)	580	<500	<500
	[<500–750]	[<500–680]	[<500–700]
AIDS-related deaths (men, 15+)	<500	<500	560
	[<500–580]	[<500–640]	[<500–750]
People living with HIV			
People living with HIV (all ages)	21 000	24 000	27 000
	[17 000–26 000]	[20 000–30 000]	[21 000–35 000]
eople living with HIV (0–14)	2300	2200	2200
	[1800–2900]	[1700–2800]	[1600–2900]
People living with HIV (women, 15+)	11 000	13 000	15 000
	[8800–13 000]	[11 000–16 000]	[12 000–20 000]
People living with HIV (men, 15+)	7600	8700	9500
	[6000–9500]	[6900–11 000]	[7500–13 000]
HIV prevalence (15–49)	1.9 [1.6–2.3]	1.9 [1.5–2.3]	1.8 [1.4–2.3]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes	2013	2018
towards people living with HIV (2018 refers to women only)	51	72.3
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		•••

EXPENDITURES						
		Finar	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2019 ... US\$ 1 019 975 ... ... ... US\$ 1 019 975




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).



<sup>\*\*</sup> Programme data—not representative; includes people with negative results.

#### **HIV TESTING AND TREATMENT CASCADE**



## **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	46% [37–58%]	46% [36-60%]
Final vertical transmission rate including during breastfeeding	27.9% [24.7–30.7%]	28.9% [25.5–32.5%]
Early infant diagnosis	% [–%]	14% [10.6–17.6%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	790 [590–1000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2013)	
— Women	25.8%
— Men	32.3%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2013)	
— Women	32.3%
— Men	67.2%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not

Not applicable
Not applicable
15

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy

— Naloxone available (2021)

- Safe injection rooms available (2021)

**GHANA COUNTRY DATA** 


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	24 000	23 000	19 000
	[20 000–30 000]	[19 000–29 000]	[14 000–25 000]
New HIV infections (0–14)	5600	4900	3700
	[4500–6800]	[3600–6200]	[2400–5100]
New HIV infections (women, 15+)	12 000	12 000	11 000
	[9500–15 000]	[9400–15 000]	[7700–14 000]
New HIV infections (men, 15+)	6800	5900	4600
	[5500–9100]	[4700–8500]	[3400–7000]
HIV incidence per 1000 population	1.02 [0.84–1.27]	0.84 [0.69–1.1]	0.63 [0.47–0.85]
AIDS-related deaths			
AIDS-related deaths (all ages)	20 000	16 000	13 000
	[17 000–24 000]	[13 000–21 000]	[10 000–17 000]
AIDS-related deaths (0–14)	4600	3600	3000
	[3900–5400]	[2800–4500]	[2200–3900]
AIDS-related deaths (women, 15+)	10 000	7800	5100
	[8400–12 000]	[6100–10 000]	[3800–7000]
AIDS-related deaths (men, 15+)	5200	5100	4700
	[4200–6800]	[4100–6600]	[3800–6100]
People living with HIV			
People living with HIV (all ages)	310 000	330 000	350 000
	[270 000–360 000]	[290 000–380 000]	[300 000–410 000]
People living with HIV (0-14)	42 000	35 000	29 000
	[36 000–48 000]	[29 000–41 000]	[23 000–35 000]
People living with HIV (women, 15+)	170 000	190 000	220 000
	[150 000–200 000]	[170 000–220 000]	[190 000–250 000]
People living with HIV (men, 15+)	94 000	100 000	100 000
	[82 000–110 000]	[90 000 <b>–1</b> 20 000]	[89 000–120 000]
HIV prevalence (15–49)	2 [1.7–2.2]	1.8 [1.6–2.1]	1.7 [1.4–1.9]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

years who report discriminatory attitudes towards people living with HIV	 
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months	<b>2014</b> 1.4
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent	<b>2014</b> 7.9
VIOLENCE	
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months	

STIGMA AND DISCRIMINATION


<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2018	US\$ 11 074 132	US\$ 34 124 926	US\$ 9 082 121	US\$ 12 083 138	US\$ 348 411	US\$ 67 413 057



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	6.9%	18%			0.4%
HIV testing and status awareness					
Antiretroviral therapy coverage	99%	3.7%			100%
Condom use	89.9%				
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2018)	2 575 600				

#### **HIV TESTING AND TREATMENT CASCADE**



## **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

2010	2020
33%	72%
[27–39%]	[57–86%]
31.4%	20.8%
[29.6–33.3%]	[16.7–24.1%]
<1%	41.4%
[<1–1.1%]	[34.7–51.8%]
	33% [27–39%] 31.4% [29.6–33.3%] <1%

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	8600 [4100 –15 000]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	19.9%
— Men	27.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	17.1%
— Men	39.1%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2014)	Not applicable

Not

applicable

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects

Voluntary medical male circumcisions

performed according to national standards

People who received PrEP at least once

during the reporting period

- Coverage of opioid substitution therapy — Naloxone available (2021)
- Safe injection rooms available (2021)

GUINEA COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	8000	7100	5300
	[7300–9000]	[6500–8000]	[4800–5900]
New HIV infections (0–14)	1900	1800	920
	[1700–2100]	[1500–2000]	[780–1100]
New HIV infections (women, 15+)	3700	3500	2900
	[3300–4400]	[3100–4100]	[2500–3400]
New HIV infections (men, 15+)	2400	1900	1400
	[2100–2800]	[1700–2300]	[1300–1800]
HIV incidence per 1000 population	0.82 [0.75–0.92]	0.65 [0.59–0.73]	0.42 [0.38–0.47]
AIDS-related deaths			
AIDS-related deaths (all ages)	3900	3700	3300
	[3500–4500]	[3100–4300]	[2900–3800]
AIDS-related deaths (0–14)	1400	1100	790
	[1300–1500]	[870–1200]	[630–900]
AIDS-related deaths (women, 15+)	1700	1400	1200
	[1400–2100]	[1100–1800]	[990–1500]
AIDS-related deaths (men, 15+)	790	1200	1300
	[630–1000]	[970–1500]	[1000–1600]
People living with HIV			
People living with HIV (all ages)	92 000	100 000	110 000
	[88 000–98 000]	[99 000–110 000]	[110 000–120 000]
People living with HIV (0–14)	12 000	11 000	9700
	[10 000–13 000]	[9200–12 000]	[8200–11 000]
People living with HIV (women, 15+)	51 000	60 000	68 000
	[49 000–55 000]	[56 000–64 000]	[64 000–73 000]
People living with HIV (men, 15+)	29 000	33 000	36 000
	[27 000–33 000]	[31 000–37 000]	[33 000–39 000]
HIV prevalence (15–49)	1.6 [1.6–1.6]	1.6 [1.5–1.6]	1.4 [1.4–1.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	N	
Percentage of women and men aged 15–49 years who report discriminatory attitudes	2016	2018
towards people living with HIV (2018 refers to women only)	80	79.7
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		•••
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total

Last available report: 2020 ... US\$ 1 383 049 ... US\$ 25 567 092 ... US\$ 34 475 926




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	10.7%	11.4%			2.3%
HIV testing and status awareness	80.1%	97.5%**	11.0%		
Antiretroviral therapy coverag	61.7%	55.5%			
Condom use	93.5%	65.5%	49.1%		
Coverage of HIV prevention programmes	65%	17.1%			
Avoidance of health care because of stigma and discrimination	1.5%				
Expenditures in US\$					

<sup>\*\*</sup> Programme data—not representative; includes people with negative results.

#### **HIV TESTING AND TREATMENT CASCADE**



## **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	20% [16–22%]	94% [78–100%]
Final vertical transmission rate including during breastfeeding	35.9% [34.2–37.7%]	16.6% [15.3–17.9%]
Early infant diagnosis	5.3% [4.4–6.7%]	43.2% [39.2–52.2%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	5400 [3500 –7700]
People living with HIV who started TB preventive therapy (2018)	32.2%
Women who tested positive for HIV among those screened for cervical cancer (programme data) (2018)	55.9%
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION  Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	20.7%
— Men	24.5%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	28.6%
— Men	49.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	


Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

# **GUINEA-BISSAU**

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	3200	2200	1700
	[2800–3800]	[1800–2700]	[1300–2000]
New HIV infections (0–14)	850	<500	<500
	[730–1000]	[<500–540]	[<500–590]
New HIV infections (women, 15+)	1400	1100	770
	[1100–1700]	[910–1400]	[580–950]
New HIV infections (men, 15+)	970	670	<500
	[790–1200]	[530–850]	[<500–520]
HIV incidence per 1000 population	2.24 [1.91–2.66]	1.35 [1.09–1.64]	0.88 [0.7–1.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	2100	1900	1500
	[1800–2500]	[1500–2200]	[1200–1800]
AIDS-related deaths (0–14)	610	<500	<500
	[540–710]	[<500-<500]	[<500-<500]
AIDS-related deaths (women, 15+)	920	770	<500
	[760–1100]	[580–950]	[<500–630]
AIDS-related deaths (men, 15+)	590	740	660
	[<500–800]	[620–920]	[540–810]
People living with HIV			
People living with HIV (all ages)	36 000	38 000	37 000
	[32 000–41 000]	[34 000–42 000]	[33 000–41 000]
People living with HIV (0–14)	4600	4000	3500
	[4100–5200]	[3500–4600]	[2900–4100]
People living with HIV (women, 15+)	19 000	21 000	22 000
	[17 000–21 000]	[18 000–23 000]	[20 000–24 000]
People living with HIV (men, 15+)	13 000	13 000	12 000
	[11 000–15 000]	[11 000–15 000]	[10 000–14 000]
HIV prevalence (15–49)	3.9 [3.6–4.4]	3.6 [3.3–4]	3 [2.7–3.4]



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2010		US\$ 611 774			US\$ 3 959 113	US\$ 5 258 837


**COUNTRY DATA** 

#### **HIV TESTING AND TREATMENT CASCADE**

75% [67–84%]

61% [53–69%]

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	14% [12–17%]	57% [46–66%]		
Final vertical transmission rate including during breastfeeding	35.7% [34–37.4%]	23.4% [21–25.4%]		
Early infant diagnosis	% [–%]	17.3% [15–21.4%]		

40% [35–46%]


4778

...% [...-...%]

...% [...-...%]

## **LIBERIA**

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2500	1900	1400
	[2000–3200]	[1400–2700]	[810–2200]
New HIV infections (0–14)	660	<500	<500
	[<500–840]	[<500–530]	[<200–<500]
lew HIV infections (women, 15+)	1100	970	730
	[800–1400]	[670–1300]	[<500–1100]
New HIV infections (men, 15+)	790	610	<500
	[590–1000]	[<500–850]	[<500–670]
HIV incidence per 1000 population	0.67 [0.53–0.85]	0.45 [0.32–0.62]	0.29 [0.17–0.45]
AIDS-related deaths			
AIDS-related deaths (all ages)	2900	2300	1300
	[2400–3500]	[1900–2800]	[1000–1800]
AIDS-related deaths (0–14)	570	<500	<200
	[<500–680]	[<500–<500]	[<200–<500]
AIDS-related deaths (women, 15+)	1300	1000	<500
	[1100–1600]	[810–1200]	[<500–650]
AIDS-related deaths (men, 15+)	990	940	660
	[810–1300]	[790–1100]	[520–830]
People living with HIV			
People living with HIV (all ages)	39 000	37 000	35 000
	[34 000–46 000]	[32 000–44 000]	[29 000–43 000]
People living with HIV (0–14)	5200	4100	2800
	[4400–6100]	[3300–4900]	[2100–3700]
eople living with HIV (women, 15+)	20 000	20 000	20 000
	[17 000–23 000]	[17 000–23 000]	[17 000–24 000]
eople living with HIV (men, 15+)	14 000	13 000	12 000
	[12 000–17 000]	[11 000–16 000]	[9800–15 000]
HIV prevalence (15–49)	1.7 [1.5–1.9]	1.4 [1.2–1.6]	1.1 [0.9–1.4]




<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2015	US\$ 8130			US\$ 10 272 345		US\$ 10 280 475

**COUNTRY DATA** 

#### **HIV TESTING AND TREATMENT CASCADE**

Men (15+)



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION				
	2010	2020		
Percentage of pregnant women living with HIV accessing antiretroviral medicines	26% [21–33%]	81% [62–100%]		
Final vertical transmission rate including during breastfeeding	31.3% [29.2–32.7%]	17.1% [11.8–21.5%]		
Early infant diagnosis	4.1% [3.2–5.7%]	20.1% [15.7–26.4%]		

37% [30–45%]

4457

27% [22–33%]

55% [45–67%]

MALI COUNTRY DATA


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7700	6400	5100
	[5900–10 000]	[4500–8500]	[3300–8300]
New HIV infections (0–14)	2700	2300	2100
	[2200–3400]	[1700–3000]	[1500–2800]
New HIV infections (women, 15+)	2800	2300	1700
	[2000–3600]	[1500–3300]	[1000–2900]
New HIV infections (men, 15+)	2200	1800	1400
	[1600–2900]	[1300–2500]	[810–2300]
HIV incidence per 1000 population	0.54 [0.41–0.7]	0.39 [0.27–0.51]	0.27 [0.17–0.43]
AIDS-related deaths			
AIDS-related deaths (all ages)	6400	6100	4600
	[5100–7900]	[4700–7600]	[3300–6300]
AIDS-related deaths (0–14)	2200	1800	1500
	[1800–2600]	[1300–2200]	[1100–1900]
AIDS-related deaths (women, 15+)	2400	2000	1400
	[1800–3100]	[1500–2600]	[1000–2000]
AIDS-related deaths (men, 15+)	1900	2300	1600
	[1500–2300]	[1800–2700]	[1200–2100]
People living with HIV			
People living with HIV (all ages)	120 000	110 000	110 000
	[99 000–130 000]	[95 000–140 000]	[90 000 <b>–1</b> 30 000]
People living with HIV (0-14)	19 000	16 000	14 000
	[16 000–22 000]	[14 000–20 000]	[11 000–18 000]
People living with HIV (women, 15+)	57 000	58 000	59 000
	[48 000–66 000]	[49 000–70 000]	[49 000–72 000]
People living with HIV (men, 15+)	40 000	39 000	37 000
	[34 000–47 000]	[32 000–46 000]	[30 000–45 000]
HIV prevalence (15–49)	1.3 [1.1–1.5]	1.1 [0.9–1.4]	0.9 [0.7–1.1]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	No specific legislation
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2015 refers to women only)	<b>2013</b> 45.8	<b>2015</b> 55.9
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2013	2018
physical or sexual violence from a male intimate partner in the past 12 months	26.6	20.9

STIGMA AND DISCRIMINATION


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019		US\$ 6 094 200	US\$ 4 500 000	US\$ 20 632 751		US\$ 33 224 961



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population					
HIV prevalence	8.7%	12.6%		11.7%	1.6%
HIV testing and status awareness	100%	95.1%		100%	
Antiretroviral therapy coverag					
Condom use	98%	75.9%	41.8%	60.6%	
Coverage of HIV prevention programmes				54.4%	
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

## **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

2010	2020
28%	28%
[24–34%]	[23–36%]
31.3%	30.6%
[29.2–33.4%]	[27.5–33.2%]
6.1%	13.4%
[5.1–7.4%]	[10.6–16.7%]
	28% [24–34%] 31.3% [29.2–33.4%] 6.1%

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	1000 [670–1500]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### **HIV PREVENTION**

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	15.6%
— Men	16.2%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	15.3%
— Men	39.1%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	41.4%
Men aged 15–49 years who are circumcised (2013)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	258
Harm reduction	
<ul> <li>Use of sterile injecting equipment at</li> </ul>	

Use of sterile injecting equipment at last injection	
<ul> <li>Needles and syringes distributed per person who injects (2017)</li> </ul>	2
<ul> <li>Coverage of opioid substitution therapy</li> </ul>	
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	No

EPIDEMIC ESTIMATES				
	2010	2015	2020	
New HIV infections				
New HIV infections (all ages)				
	[–]	[=]	[=]	
New HIV infections (0–14)				
	[]	[=]	[=]	
New HIV infections (women, 15+)				
	[]	[=]	[=]	
New HIV infections (men, 15+)				
	[]	[]	[]	
HIV incidence per 1000 population	[]	[]	[]	
AIDS-related deaths				
AIDS-related deaths (all ages)	530	550	<500	
	[<500–630]	[<500 <u>–</u> 680]	[<500–590]	
AIDS-related deaths (0–14)	<100	<100	<100	
	[<100- <200]	[<100-<100]	[<100- <100]	
AIDS-related deaths (women, 15+)	<200	<200	<200	
	[<200– <200]	[<200–<500]	[<200–<500]	
AIDS-related deaths (men, 15+)	<500	<500	<500	
	[<500-<500]	[<500-<500]	[<200-<500]	
People living with HIV				
People living with HIV (all ages)	9600	9000	8500	
	[8400–11 000]	[7700–11 000]	[7000–11 000]	
People living with HIV (0-14)	820	710	650	
	[730–930]	[610–820]	[540–800]	
People living with HIV (women, 15+)	3700	3700	3700	
	[3200–4100]	[3100–4300]	[3100–4600]	
People living with HIV (men, 15+)	5100	4700	4200	
	[4400–6000]	[3900–5500]	[3400–5300]	
HIV prevalence (15–49)	0.5 [0.4–0.6]	0.4 [0.3–0.5]	0.3 [0.2–0.4]	


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, death penalty
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2015 refers to women only)	<b>2011</b> 70.5	<b>2015</b> 76
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months		

STIGMA AND DISCRIMINATION

EXPENDITURES						
Financing sources						
Domestic private Domestic public International: International: Total PEPFAR Global Fund all others						


Last available report: 2013 ... ... ... US\$ 1 915 820 ... US\$ 2 731 148



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

#### **KEY POPULATIONS** Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population HIV prevalence 9% 23.4% HIV testing and status awareness Antiretroviral therapy coverage Condom use Coverage of HIV prevention ... ... ... programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

#### **HIV TESTING AND TREATMENT CASCADE**



# ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION 2010 2020 Percentage of pregnant women living with HIV 9% 20% accessing antiretroviral medicines [8–11%] [15–26%]

...%

...%

breastfeeding	[%]	[%]
Early infant diagnosis	%	%
Larry Illiant diagnosis	[%]	[%]

Final vertical transmission rate including during

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	120 [33–270]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### **HIV PREVENTION**

Adults	aged	15+	years	with	unsuppressed
viral lo	ad				

Knowledge of HIV prevention among young people aged 15–24 years (2015)

— Women	8.3%
— Men	8.9%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years

- Women
- Men

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
- Safe injection rooms available (2021)

**NIGER COUNTRY DATA** 

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	1300	1300	1200
	[1000–1600]	[1100–1600]	[910–1400]
New HIV infections (0–14)	<500	<500	<500
	[<500– <500]	[<500–590]	[<500–570]
New HIV infections (women, 15+)	600	510	<500
	[<500–730]	[<500–620]	[<500–<500]
New HIV infections (men, 15+)	<500	<500	<500
	[<500-<500]	[<500–<500]	[<500–<500]
HIV incidence per 1000 population	0.08 [0.06–0.1]	0.07 [0.06–0.08]	0.05 [0.04–0.06]
AIDS-related deaths			
AIDS-related deaths (all ages)	2200	1700	1100
	[1800–2700]	[1300–2000]	[870–1300]
AIDS-related deaths (0–14)	520	<500	<500
	[<500–610]	[<500-<500]	[<500-<500]
AIDS-related deaths (women, 15+)	630	<500	<500
	[<500–830]	[<500–550]	[<500–<500]
AIDS-related deaths (men, 15+)	1100	870	<500
	[830–1300]	[700–1100]	[<500–590]
People living with HIV			
People living with HIV (all ages)	37 000	33 000	31 000
	[33 000–42 000]	[30 000–37 000]	[28 000–35 000]
People living with HIV (0–14)	5200	4000	3200
	[4500–6000]	[3400–4700]	[2700–3700]
People living with HIV (women, 15+)	16 000	16 000	17 000
	[14 000–18 000]	[15 000–18 000]	[15 000–19 000]
People living with HIV (men, 15+)	16 000	13 000	12 000
	[14 000–18 000]	[12 000–15 000]	[10 000–13 000]
HIV prevalence (15–49)	0.4 [0.4–0.5]	0.3 [0.3–0.3]	0.2 [0.2–0.2]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 16 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

#### **STIGMA AND DISCRIMINATION**

Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	<b></b>	
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their		•••


## **VIOLENCE**

consent

Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male intimate partner in the past 12 months

EXPENDITURES						
Financing sources						
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total


US\$ 9949 US\$ 5 496 393 US\$ 7 110 841 Last available report: 2020



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

#### **KEY POPULATIONS** Men who People who Transgender Sex workers Prisoners have sex inject drugs people with men Estimated size of population 53 700 ... **HIV** prevalence 9.5% 6.4% HIV testing and status 83.7% 57.5% awareness Antiretroviral therapy coverage Condom use 92 7% 89.6% Coverage of HIV prevention 58.3% 53.4% ... programmes Avoidance of health care because of stigma and discrimination **Expenditures in US\$**

## **HIV TESTING AND TREATMENT CASCADE**



#### ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	89% [77–100%]	36% [32–40%]
Final vertical transmission rate including during breastfeeding	14.1% [11.5–16.5%]	27.4% [25–29%]
Early infant diagnosis	% [–%]	2.9% [2.6–3.2%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	800 [510–1100]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2016)	
— Women	15.8%
— Men	25.5%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2012)	
— Women	35.1%
— Men	64.3%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised	Not

Men aged 15–49 years who are circumcised	Not applicable	
Voluntary medical male circumcisions performed according to national standards	Not applicable	
People who received PrEP at least once during the reporting period		

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021)
  Safe injection rooms available (2021)
  No

NIGERIA COUNTRY DATA


PIDEMIC ESTIMATES			
	2010	2015	2020
ew HIV infections			
ew HIV infections (all ages)	110 000	95 000	86 000
	[63 000–210 000]	[52 000–170 000]	[47 000–150 000]
ew HIV infections (0–14)	25 000	17 000	21 000
	[14 000–41 000]	[9800–28 000]	[12 000–34 000]
ew HIV infections (women, 15+)	50 000	46 000	39 000
	[26 000–94 000]	[24 000–86 000]	[20 000–75 000]
ew HIV infections (men, 15+)	41 000	33 000	25 000
	[21 000–78 000]	[17 000–63 000]	[13 000–49 000]
V incidence per 1000 population	0.72 [0.39–1.31]	0.53 [0.29–0.95]	0.42 [0.23–0.76]
DS-related deaths			
DS-related deaths (all ages)	68 000	48 000	<b>49</b> 000
	[42 000–110 000]	[29 000–78 000]	[30 000–80 000]
DS-related deaths (0–14)	18 000	11 000	12 000
	[10 000–30 000]	[6500–19 000]	[7000–21 000]
DS-related deaths (women, 15+)	26 000	16 000	16 000
	[15 000–44 000]	[9100–27 000]	[9300–28 000]
DS-related deaths (men, 15+)	25 000	20 000	20 000
	[15 000–41 000]	[13 000–34 000]	[12 000–33 000]
eople living with HIV			
eople living with HIV (all ages)	1 400 000	1 600 000	1 700 000
	[1 100 000–1 900 000]	[1 200 000–2 100 000]	[1 300 000–2 300 000]
eople living with HIV (0–14)	150 000	130 000	130 000
	[100 000–230 000]	[89 000–200 000]	[85 000–190 000]
cople living with HIV (women, 15+)	710 000	840 000	960 000
	[530 000–940 000]	[630 000 <b>–1</b> 100 000]	[720 000 <b>–1</b> 300 000]
eople living with HIV (men, 15+)	550 000	610 000	650 000
	[420 000–740 000]	[460 000–820 000]	[490 000–860 000]
V prevalence (15–49)	1.4 [1.1–1.9]	1.4 [1–1.9]	1.3 [0.9–1.7]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No


Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV	2016	2018
(2018 refers to women only)	52.8	59.2
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced physical or sexual violence from a male	2013	2018
intimate partner in the past 12 months	10.9	13.8


STIGMA AND DISCRIMINATION

<b>EXPENDITURES</b>						
		Fina	ancing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2020	US\$ 197 273	US\$ 91 477 781	US\$ 355 296 799	US\$ 80 370 485	US\$ 4 771 460	US\$ 532 371 498









Change in new **HIV** infections since 2010

Change in AIDS--28% related deaths since 2010

Incidence: 4.94 prevalence ratio

mortality ratio\*


<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			326 100		
HIV prevalence	16.7%	20.9%	6.2%	18.5%	2.8%
HIV testing and status awareness	69.0%	58.5%	37.2%	59.0%	
Antiretroviral therapy coverage	23.7%	26.3%	25%	19.5%	
Condom use	85.5%	69.8%	46.5%	65.9%	
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

HIV	CON	ЛOF	RBIC	ITIC	ES

Estimated number of incident tuberculosis cases among people living with HIV (2018)	53 000 [34 000 -75 000]
People living with HIV who started TB preventive therapy (2018)	61.6%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### **HIV TESTING AND TREATMENT CASCADE**



#### LIV DDEVENITION

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.3%
Knowledge of HIV prevention among young people aged 15–24 years (2018)	
— Women	42.6%
— Men	33.7%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2018)	
— Women	35.7%
— Men	64.6%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2018)	35.7%
Men aged 15–49 years who are circumcised (2013)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once	37 736

#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	31% [21–44%]	44% [30–63%]
Final vertical transmission rate including during breastfeeding	30.4% [24.8–36.1%]	24.9% [20.4–29.6%]
Early infant diagnosis	9.6% [6.6–14.7%]	23.4% [16.4–34.5%]

#### Harm reduction

during the reporting period (2020)


Use of sterile injecting equipment at last injection	
<ul> <li>Needles and syringes distributed per person who injects (2020)</li> </ul>	0
<ul> <li>Coverage of opioid substitution therapy</li> </ul>	
— Naloxone available (2021)	Yes

- Safe injection rooms available (2021)

# SAO TOME AND PRINCIPE

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	1.4%	3.2%			8.2%
HIV testing and status awareness	100%	100%			
Antiretroviral therapy coverag			•••		5.9%
Condom use	43.8%	60.8%			
Coverage of HIV prevention programmes	22.6%	82.5%			
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

#### **HIV TESTING AND TREATMENT CASCADE**



HIV COMORBIDITIES	
Estimated number of incident tuberculosis cases among people living with HIV (2018)	38 [13–78]
People living with HIV who started TB preventive therapy (2018)	8.7%
Cervical cancer screening of women living with HIV	

#### **HIV PREVENTION**

People coinfected with HIV and hepatitis C virus starting hepatitis C treatment

Adults aged 15+ years with unsuppressed viral load	<0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	42.2%
— Men	43.2%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15-49

49 years		
— Women		
— Men		

Women aged 15-49 years who have their demand for family planning satisfied by modern methods

Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period	
Hama vaduation	

Harm reduction

 III I Caaction	
<ul> <li>Use of sterile injecting equipment at last injection</li> </ul>	
<ul> <li>Needles and syringes distributed per person who injects</li> </ul>	
<ul> <li>Coverage of opioid substitution therapy</li> </ul>	
— Naloxone available (2021)	

- Safe injection rooms available (2021)

EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014	US\$ 25 403	US\$ 30 800			US\$ 235 140	US\$ 751 806

#### **COUNTRY DATA**

LAWS AND POLICIES		STIGMA AND DISCRIMINATION			
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	No, but prosecutions exist based on general criminal laws	Percentage of women and men aged 15–49 years who report discriminatory attitudes			
Criminalization of sex work among consenting adults	Sex work is not subject to punitive regulations or is not criminalized	towards people living with HIV			
Criminalization of same-sex sexual acts	No specific legislation	Percentage of people living with HIV denied health services because of their HIV status in the last 12 months			
Drug use or possession for personal use is an offence		Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their			
Criminalization of transgender people	Neither criminalized nor prosecuted	others about their HIV status without their consent			
Laws or policies restricting the entry, stay and residence of people living with HIV	No	VIOLENCE			
Parental consent for adolescents to access HIV testing	No	Proportion of ever-married or partnered women aged 15–49 years who experienced			
Spousal consent for married women to access sexual and reproductive health services	No	physical or sexual violence from a male intimate partner in the past 12 months			
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No				

SENEGAL


EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	2100	1300	1200
	[1800–2600]	[1100–1600]	[960–1600]
New HIV infections (0–14)	930	550	<500
	[770–1200]	[<500–670]	[<500-<500]
New HIV infections (women, 15+)	580	<500	<500
	[<500–730]	[<500-<500]	[<500–600]
New HIV infections (men, 15+)	630	<500	<500
	[510–810]	[<500–540]	[<500–670]
HIV incidence per 1000 population	0.18 [0.15–0.21]	0.1 [0.08–0.12]	0.08 [0.06–0.1]
AIDS-related deaths			
AIDS-related deaths (all ages)	1900	2100	1100
	[1500–2500]	[1600–2600]	[890–1300]
AIDS-related deaths (0–14)	710	550	<500
	[590–860]	[<500–660]	[<500-<500]
AIDS-related deaths (women, 15+)	<500	560	<500
	[<200-<500]	[<500–800]	[<500–<500]
AIDS-related deaths (men, 15+)	980	990	550
	[710–1300]	[770–1200]	[<500–680]
People living with HIV			
People living with HIV (all ages)	47 000	42 000	39 000
	[41 000–54 000]	[37 000–47 000]	[35 000–44 000]
People living with HIV (0–14)	6200	5300	<b>3900</b>
	[5300–7300]	[4600–6200]	[3300–4600]
People living with HIV (women, 15+)	21 000	21 000	21 000
	[18 000–25 000]	[19 000–23 000]	[19 000–24 000]
People living with HIV (men, 15+)	19 000	16 000	14 000
	[17 000–22 000]	[14 000–17 000]	[13 000–16 000]
HIV prevalence (15–49)	0.6 [0.5–0.7]	0.4 [0.4–0.5]	0.3 [0.3–0.4]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 14 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

STIGMA AND DISCRIMINATION	NC	
Percentage of women and men aged 15–49 years who report discriminatory attitudes towards people living with HIV (2017 refers to women only)	<b>2013</b> 53.4	<b>2017</b> 65.5
Percentage of people living with HIV denied health services because of their HIV status in the last 12 months		<b>2012</b> 2.7
Percentage of people living with HIV who reported a health-care professional told others about their HIV status without their consent		
VIOLENCE		
Proportion of ever-married or partnered women aged 15–49 years who experienced	2017	2019
physical or sexual violence from a male intimate partner in the past 12 months	12.2	10.2

**COUNTRY DATA** 


<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2014	US\$ 1 677 138	US\$ 2 033 864		US\$ 10 826 741	US\$ 2 654 137	US\$ 17 191 880



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS						
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners	
Estimated size of population		52 500	***	•••	9 500	
HIV prevalence	4.8%	27.6%	3.7%		2%	
HIV testing and status awareness	98.0%	63.4%	100%			
Antiretroviral therapy coverag	28.3%	37.8%				
Condom use	91.6%	75.8%	54.1%			
Coverage of HIV prevention programmes	65.5%	6.4%				
Avoidance of health care because of stigma and discrimination	19.1%					
Expenditures in US\$ (2014)	253 522	448 688	171 534			

#### **HIV TESTING AND TREATMENT CASCADE**



ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION		
	2010	2020
Percentage of pregnant women living with HIV accessing antiretroviral medicines	21% [19–25%]	74% [66–84%]
Final vertical transmission rate including during breastfeeding	27.4% [25–29.7%]	16.1% [14–19.6%]
Early infant diagnosis	11%	34.9%

[9.6-12.7%]

[30.7-39.4%]

Early infant diagnosis

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	910 [640–1200]
People living with HIV who started TB preventive therapy (2018)	10.4%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	0.1%
Knowledge of HIV prevention among young people aged 15–24 years (2017)	
— Women	26.2%
— Men	33.1%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2017)	
— Women	41.8%
— Men	70.8%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods (2017)	54.1%
Men aged 15–49 years who are circumcised	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable
People who received PrEP at least once during the reporting period (2020)	83

#### Harm reduction

<ul> <li>Use of sterile injecting equipment at last injection</li> </ul>	
<ul> <li>Needles and syringes distributed per person who injects (2020)</li> </ul>	16
<ul> <li>Coverage of opioid substitution therapy (2020)</li> </ul>	10.4%
— Naloxone available (2021)	No

No

- Safe injection rooms available (2021)

# **SIERRA LEONE**


**COUNTRY DATA** 

	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	6500	6200	5400
	[5500–7600]	[5100–7200]	[3900–7100]
New HIV infections (0–14)	2300	2000	2000
	[1800–2800]	[1500–2500]	[1400–2500]
New HIV infections (women, 15+)	2300	2500	2100
	[1900–2800]	[2000–3000]	[1500–3000]
New HIV infections (men, 15+)	1900	1700	1300
	[1600–2300]	[1300–2100]	[850–1800]
HIV incidence per 1000 population	1.05 [0.9–1.22]	0.9 [0.74–1.05]	0.7 [0.51–0.92]
AIDS-related deaths			
AIDS-related deaths (all ages)	4400	4200	3200
	[3700–5400]	[3500–4900]	[2700–3800]
AIDS-related deaths (0–14)	1700	1500	1400
	[1400–2100]	[1200–1800]	[1000–1700]
AIDS-related deaths (women, 15+)	1400	1200	720
	[1100–1800]	[900–1500]	[530–930]
AIDS-related deaths (men, 15+)	1200	1500	1100
	[980–1600]	[1200–1800]	[930–1400]
People living with HIV			
People living with HIV (all ages)	66 000	73 000	80 000
	[59 000–76 000]	[66 000–82 000]	[70 000–90 000]
People living with HIV (0–14)	13 000	12 000	11 000
	[11 000–16 000]	[10 000–15 000]	[9000–14 000]
People living with HIV (women, 15+)	30 000	36 000	42 000
	[27 000–34 000]	[32 000–40 000]	[37 000–48 000]
People living with HIV (men, 15+)	23 000	25 000	26 000
	[20 000–27 000]	[22 000–28 000]	[23 000–30 000]
HIV prevalence (15–49)	1.6 [1.4–1.8]	1.6 [1.4–1.8]	1.5 [1.3–1.7]

LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	Yes, for adolescents younger than 18 years
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

NC	
<b>2011</b> 51.2	<b>2017</b> 72.1
	<b>2013</b> 1.2
<b>2013</b> 28.6	<b>2019</b> 39.9
	51.2


<b>EXPENDITURES</b>						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2011	US\$ 40 385	US\$ 168 584	US\$ 2 957 997	US\$ 3000	US\$ 3 394 829	US\$ 20 905 243



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population			•••	•••	
HIV prevalence	6.7%	14%	8.5%	15.3%	8.7%
HIV testing and status awareness					
Antiretroviral therapy coverag					
Condom use					
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$					

#### **HIV TESTING AND TREATMENT CASCADE**



#### **ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION**

2010	2020
23%	46%
[19–28%]	[37-55%]
29.2%	23.1%
[27.8–30.8%]	[20.4–25.3%]
<1%	2.8%
[<1– <1%]	[2.4–3.6%]
	23% [19–28%] 29.2% [27.8–30.8%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	2900 [1900 –4200]
People living with HIV who started TB preventive therapy (2018)	56.7%
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

#### **HIV PREVENTION**

Adults aged 15+ years with unsuppressed viral load

Knowledge of HIV prevention among young people aged 15–24 years (2013)

— Women	28.8%
— Men	30%

Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2013)

— Women	6.8%
— Men	19.4%

Women aged 15–49 years who have their demand for family planning satisfied by modern methods

performed according to national standards

Men aged	15-49 years	who are	circumcised	Not
(2013)				applicable

Voluntary medical male circumcisions	Not	

applicable

People who received PrEP at least once during the reporting period	

#### Harm reduction

- Use of sterile injecting equipment at last injection
- Needles and syringes distributed per person who injects
- Coverage of opioid substitution therapy
- Naloxone available (2021) No
- Safe injection rooms available (2021)

TOGO **COUNTRY DATA** 

EPIDEMIC ESTIMATES			
	2010	2015	2020
New HIV infections			
New HIV infections (all ages)	7500	5200	3600
	[6800–8400]	[4800–5900]	[3300–3900]
New HIV infections (0–14)	2300	1300	1200
	[1900–2500]	[960–1600]	[820–1400]
New HIV infections (women, 15+)	3100	2500	1600
	[2700–3700]	[2100–2900]	[1400–1900]
New HIV infections (men, 15+)	2200	1500	810
	[1900–2600]	[1200–1800]	[690–1000]
HIV incidence per 1000 population	1.24 [1.13–1.4]	0.76 [0.69–0.86]	0.45 [0.42–0.5]
AIDS-related deaths			
AIDS-related deaths (all ages)	6600	4600	3000
	[6100–7400]	[4100–5300]	[2600–3400]
AIDS-related deaths (0–14)	1900	1100	810
	[1700–2000]	[840–1200]	[580–940]
AIDS-related deaths (women, 15+)	2800	1600	960
	[2500–3300]	[1300–2000]	[790–1200]
AIDS-related deaths (men, 15+)	1900	1900	1200
	[1700–2300]	[1700–2300]	[1000–1500]
People living with HIV			
People living with HIV (all ages)	110 000	110 000	110 000
	[110 000–120 000]	[110 000–120 000]	[110 000–120 000]
People living with HIV (0-14)	17 000	13 000	9700
	[16 000–18 000]	[11 000–14 000]	[7700–11 000]
People living with HIV (women, 15+)	58 000	62 000	66 000
	[55 000–62 000]	[59 000–66 000]	[62 000–70 000]
People living with HIV (men, 15+)	38 000	39 000	36 000
	[36 000–42 000]	[36 000–42 000]	[34 000–39 000]
HIV prevalence (15–49)	2.8 [2.8–2.8]	2.5 [2.4–2.5]	2 [1.9–2.1]


LAWS AND POLICIES	
Laws criminalizing the transmission of, non- disclosure of or exposure to HIV transmission	Yes
Criminalization of sex work among consenting adults	Any criminalization or punitive regulation of sex work
Criminalization of same-sex sexual acts	Yes, imprisonment (up to 14 years)
Drug use or possession for personal use is an offence	Drug use or consumption is specified as a criminal offence
Criminalization of transgender people	Neither criminalized nor prosecuted
Laws or policies restricting the entry, stay and residence of people living with HIV	No
Parental consent for adolescents to access HIV testing	No law requiring parental/guardian consent
Spousal consent for married women to access sexual and reproductive health services	No
Mandatory HIV testing for marriage, work or residence permits or for certain groups	No

residence permits or for certain groups

2020
13
•••

STIGMA AND DISCRIMINATION


EXPENDITURES						
		Fina	ncing sources			
	Domestic private	Domestic public	International: PEPFAR	International: Global Fund	International: all others	Total
Last available report: 2019	US\$ 1 964 091	US\$ 3 843 147	US\$ 2 905 953	US\$ 8 642 402	US\$ 1 467 324	US\$ 20 503 500



<sup>\*</sup> The incidence:mortality ratio is not published if the country has not achieved antiretroviral therapy coverage of 81% or higher (the testing and treatment target for 2020).

KEY POPULATIONS					
	Sex workers	Men who have sex with men	People who inject drugs	Transgender people	Prisoners
Estimated size of population	•••			•••	5 000
HIV prevalence	13.2%	22%			4.7%
HIV testing and status awareness	96.8%	95.4%	44.7%		
Antiretroviral therapy coverag	66.9%	61.7%	1%		
Condom use	86.4%	80.2%			
Coverage of HIV prevention programmes					
Avoidance of health care because of stigma and discrimination					
Expenditures in US\$ (2019)	214 380	1 072 822	10 239	9600	2010

#### **HIV TESTING AND TREATMENT CASCADE**



# ELIMINATION OF MOTHER-TO-CHILD TRANSMISSION

	2010	2020
Percentage of pregnant women living with HIV	29%	64%
accessing antiretroviral medicines	[24–32%]	[51–71%]
Final vertical transmission rate including during	31.4%	20.8%
breastfeeding	[29.9–32.8%]	[17.8–22.2%]
Early infant diagnosis	17.2%	33.4%
Early Illiant diagnosis	[13.7-23%]	[30.1-41.6%]

#### **HIV COMORBIDITIES**

Estimated number of incident tuberculosis cases among people living with HIV (2018)	490 [390–600]
People living with HIV who started TB preventive therapy (2018)	
Cervical cancer screening of women living with HIV	
People coinfected with HIV and hepatitis C virus starting hepatitis C treatment	

HIV PREVENTION	
Adults aged 15+ years with unsuppressed viral load	
Knowledge of HIV prevention among young people aged 15–24 years (2014)	
— Women	23.3%
— Men	31.6%
Condom use at last sex with a non-marital, non-cohabiting partner among people aged 15–49 years (2014)	
— Women	42.9%
— Men	60.7%
Women aged 15–49 years who have their demand for family planning satisfied by modern methods	
Men aged 15–49 years who are circumcised (2014)	Not applicable
Voluntary medical male circumcisions performed according to national standards	Not applicable

#### Harm reduction

<ul> <li>Use of sterile injecting equipment at last injection</li> </ul>	
<ul> <li>Needles and syringes distributed per person who injects (2020)</li> </ul>	2
Coverage of opioid substitution	

People who received PrEP at least once

during the reporting period

<ul> <li>Coverage of opioid substitution therapy</li> </ul>	
— Naloxone available (2021)	No
— Safe injection rooms available (2021)	Yes



UNAIDS
Joint United Nations
Programme on HIV/AIDS

20 Avenue Appia 1211 Geneva 27 Switzerland

+41 22 791 3666

unaids.org